Specific Functions of the Tumor Suppressor P53 are Activated by P73 and VHL by Wolf, Eric R.
 
 
SPECIFIC FUNCTIONS OF THE TUMOR SUPPRESSOR P53  
ARE ACTIVATED BY P73 AND VHL 
 
 
 
 
 
 
 
Eric R. Wolf 
 
 
 
 
 
 
 
Submitted to the faculty of the University Graduate School 
in partial fulfillment of the requirements  
for the degree 
 Doctor of Philosophy    
in the Department of Biochemistry and Molecular Biology,  
Indiana University 
 
July 2019 
  
ii 
Accepted by the Graduate Faculty of Indiana University, in partial 
fulfillment of the requirements for the degree of Doctor of Philosophy. 
 
 
Doctoral Committee 
 
 
  
______________________________________ 
Lindsey Mayo, PhD, Chair 
 
 
 
 
______________________________________ 
Mark Goebl, PhD 
 
 
May 9, 2019 
 
______________________________________ 
Mircea Ivan, PhD 
 
 
 
 
______________________________________ 
Marc Mendonca, PhD   
 
 
______________________________________ 
Clark Wells, PhD 
 
  
iii 
DEDICATION 
For Sam – your relentless drive to improve the lives of those who followed you 
has been an immense source of motivation for me. 
 
 
Drawing by Sam Featherstone. Printed with permission from SamStrong. 
  
iv 
ACKNOWLEDGEMENTS  
I want to acknowledge the people in my life who have helped, inspired, and 
motivated me. Emily and Jack – for always believing in me and keeping me grounded. 
My parents, Tom and Shelly, and brother, Alex – for teaching me to be curious about 
everything and providing an environment that fostered learning. My teachers and 
professors, Mrs. Ball, Mrs. Steffenhagen, and Dr. Na – for entertaining my questions and 
instilling in me an appreciation for the sciences. Additionally, I want to acknowledge the 
role that many relatives and friends have played in inspiring and motivating me through 
their own battles with cancer – my grandparents Dick and Elvira Wolf, my grandparents 
Harrison and Jessie Hicks, my uncle Gary Patrick, my uncle Joe Hicks, my sister-in-law 
Libby Storkman, my friend Sam Featherstone, my aunt-in-law Julie Mills, and my mom, 
Shelly Wolf.  
I would like to thank my advisor, Dr. Lindsey Mayo – for his mentorship and 
guidance during my graduate career. I would also like to acknowledge the members of 
my committee – Dr. Mark Goebl, Dr. Mircea Ivan, Dr. Marc Mendonca, and Dr. Clark 
Wells for their time, knowledge, and helpful insights throughout my research. I want to 
thank the past members of the Mayo lab as well – Dr. Paula Hauck, for training me at the 
bench and providing valuable technical advice; Dr. David Olivos, for our stimulating 
scientific conversations; and Ciaran McAtarsney, for being a great colleague. 
 
 
  
v 
Eric R. Wolf 
SPECIFIC FUNCTIONS OF THE TUMOR SUPPRESSOR P53  
ARE ACTIVATED BY P73 AND VHL 
The transcription factor and tumor suppressor protein p53 critically regulates cell 
survival or death in response to cellular stress. p53 can activate genes involved in a wide 
variety of processes, including apoptosis, cell cycle arrest, angiogenesis, metabolism, and 
senescence.  Mutations in p53 are common in cancer and alter its interactions with other 
proteins, but there are other mechanisms and posttranslational modifications that can alter 
these interactions as well. In some tumors, such as renal cell carcinoma, p53 is commonly 
inactive even though mutations to TP53 are rare. This suggests that there are other 
biochemical mechanisms of inhibition, which we explore in this study. 
Mutations in the DNA-binding domain of p53 result in conformational changes 
that enable p53 to interact with and inhibit its family member p73, thereby promoting cell 
survival instead of apoptosis. In contrast, it has been reported that wild-type p53 does not 
bind to p73. We found that JNK-mediated phosphorylation of Thr81 in the proline-rich 
domain (PRD) of p53 enabled wild-type p53 to form a complex with p73. The 
dimerization of wild-type p53 with p73 facilitated the expression of apoptotic target 
genes such as PUMA and BAX, as well as the induction of apoptosis. In addition to the 
apoptotic function of p53, the tumor suppressor also plays a major role in the inhibition 
of angiogenesis. 
Here we also report a new mechanism where the Mdm2 oncoprotein can 
indirectly inactive p53 through the regulation of the tumor suppressor VHL. In response 
to hypoxia, VHL can bind p53, which results in activation of several anti-angiogenic 
vi 
targets of p53 such as THBS1 and COL18A1. Mdm2 regulates the VHL-p53 interaction 
by conjugating nedd8 to VHL within a region that is important for the VHL-p53 
interaction, blocking the induction of anti-angiogenic genes and resulting in a 
proangiogenic phenotype. Due to its positive regulation of major proangiogenic proteins 
and its negative regulation of potent inhibitors of angiogenesis, we propose that the 
oncoprotein Mdm2 is the angiogenic switch. These findings refine our understanding of 
p53 interactions and activation, specifically for p53-p73 induced cell death and p53-VHL 
inhibition of angiogenesis.  
 
Lindsey Mayo, PhD, Chair 
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1. Background 
1.1 The p53 tumor suppressor family 
 The first evidence of an ancestor to the p53 family of proteins comes in sea 
anemones [2]. This ancestral gene more closely resembles p53 family members, p63 and 
p73, but its function was akin to the modern day p53 – to protect cells from DNA 
damage. It is likely that these organisms evolved to have this ancestral protein due to the 
high levels of UV they are exposed to near the surface of water. As evolution progressed, 
the appearance of the first gene that closely represents p53 came about in cartilaginous 
fish, when somatic stem cells were first used by organisms to regenerate adult tissues [2]. 
Later, with the dawn of bony fish, the p63/p73 like gene evolved to become two separate 
genes that share similarity with both p63 and p73. While all of these family members 
share similarities, they have distinct functions and protein domains as well. For instance, 
p63 has been linked to development of epithelial cells, p73 plays a role in the 
development of the immune and nervous systems, and p53 plays a major role in most 
cells in the DNA damage response [2]. p63 and p73 are both needed for a full apoptotic 
response to DNA damage. Indeed, p63 is present on promoters of p53 target genes in the 
absence of p53, but p53 is not present on a subset of these gene promoters in the absence 
of p63 and p73 [3]. This regulation suggests that p53 alone is not sufficient to promote 
tumor suppression.  
TP53 is the most mutated gene in all human cancers, and has been called the 
‘Guardian of the Genome’ for its many functions in maintaining the integrity of DNA. 
Interestingly, p63 and p73 are very rarely mutated in cancer [4]. The p53 protein 
functions as a dimer of dimers, with tight regulation of its tetramerization domain [5]. As 
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a tetramer, p53 can bind to p53-responsive sequences in the promoter region of many 
genes involved in apoptosis, cell cycle arrest, metabolism, and angiogenesis [6]. p73 and 
p53 can both activate some, but not all, genes with the consensus p53-responsive 
sequence and they are both induced via DNA damage.  
  Some interesting insights into p53 have been gained through the analysis of 
various diseases and species. The Li Fraumeni Syndrome (LFS) is a familial disease 
associated with germline mutations in TP53. Studying families with LFS has given 
researchers information about the role of various TP53 mutations in cancer [7, 8]. 
Patients with Down Syndrome have a reduced occurrence of all cancers. This is due, in 
part, to the trisomy of chromosome 21 that defines Down Syndrome. The extra copy of a 
specific gene on chromosome 21, COL18A1, has been associated with a 2-fold increase 
in serum levels of its protein product, endostatin [9]. COL18A1 is a known target of p53 
involved in the inhibition of angiogenesis. Interestingly, elephants and other trunk 
swinging mammals rarely get cancer. While the mechanisms governing this phenomenon 
are not entirely understood, it is due at least in part to the fact that the elephant genome 
encodes 20 copies of TP53 [10]. The lack of cancer in elephants is part of what is known 
as ‘Peto’s Paradox’, which states that although larger animals should have an increased 
incidence in cancer due to the increased cell count, they do not. Instead, these animals 
have evolved to have a reduced number of oncogenes in their genomes and, like TP53 in 
elephants, an increased number of tumor suppressors in their genomes.  
1.2 The p53-Mdm2 autoregulatory feedback loop  
Inactivation of p53 can happen in a variety of ways including mutation of the 
TP53 gene and the binding of the p53 protein to viral or oncogenic proteins. Mutations of 
3 
TP53 are extremely common in cancer, but there are many tumors that maintain wild 
type p53. In these tumors, p53 can be inhibited at the protein level by overexpressed 
cellular oncoproteins or by viral oncogenic proteins. In fact, p53 was originally 
discovered due to its binding to the SV40 large T antigen [11, 12]. The main cellular 
oncoprotein that inhibits p53 is the mouse double minute 2 (Mdm2) protein. The 
interaction of Mdm2 with p53 was initially discovered in rat fibroblasts as a 90 kDa 
protein complexed with p53 [13]. Importantly, this interaction was only seen when p53 
was wild type, and wild type p53 also caused an increase in MDM2 mRNA [14-16]. 
Further studies characterized Mdm2 as an inhibitor of p53 through direct transcription 
inhibition and by targeting p53 for degradation via the 26S proteasome. Mdm2 binds p53 
in its transactivation domain and causes an a-helical conformation change, which has 
been reported to inhibit the DNA binding activity of p53 [14, 17]. However, other groups 
have reported that an Mdm2-p53 complex can be found on the chromatin of p53 target 
genes, suggesting that the binding of Mdm2 to p53 does not completely block the DNA 
binding activity of p53[18]. Additionally, Mdm2 is an E3 ubiquitin ligase for p53 and in 
this manner it signals for proteasomal mediated degradation of p53 [19-24]. While Mdm2 
is the most studied E3 ubiquitin ligase for p53, there are over 20 other E3 ligases that 
regulate p53 in different contexts [25]. 
There are several reasons to explain the high number of E3 ligases for p53 
including differential expression during embryonic development, evolutionary 
conservation, and differential binding in specific PTM contexts. Trim24 and Cop1 are 
both expressed in a tissue-specific context at 10.5 dpc, while ARF-BP1 is ubiquitously 
expressed at 14.5 dpc [25]. Interestingly, deletion of Trim24 in mice caused tumor 
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formation specific to the liver [26]. Additionally, deletion of the Trim24 ancestor in 
Drosophila, bonus, results in widespread cell death due to increased activity of D-p53, the 
Drosophila version of human p53 [27]. Perhaps the most likely reason for this 
redundancy in E3 ligases is to ensure that post-translationally modified p53 can still be 
regulated. p53 is highly modified by phosphorylation, acetylation, and methylation so in 
order to regulate the protein there needs to be a complex system in place to read these 
PTMs. Bromo structural domains are known to interact with acetylated lysines, and PHD 
domains with patterns of methylated lysines. Of note, Trim24 contains a PHD-Bromo 
domain, but its ability to recognize acetylated and/or methylated p53 has not been tested. 
There are specific phosphorylation sites of p53 that inhibit its binding to Mdm2, so to 
circumvent these processes there are other E3 ligases that can likely bind to p53 
independently of PTMs. Cop1 has a WD40 domain, which facilitates protein-protein 
interactions that are not dependent on PTMs. Likewise, ARF-BP1 has a WWE domain 
which functions in a similar manner. Pirh2 is another E3 ligase of p53 that binds 
preferentially to tetramers of p53, which likely means that it functions in terminating the 
p53 response [28]. Both Pirh2 and Cop1 are also part of an autoregulatory feedback loop 
with p53, in a similar manner to Mdm2. Trim24, Cop1, ARF-BP1, and Pirh2 
ubiquitination of p53 leads to K48-linked polyubiquitination and subsequent degradation 
[27, 29]. Mdm2 may have the most diverse regulation of p53, being able to mediate K48-
linked polyubiquitination, K63-linked monoubiquitination, and neddylation. Just as the 
regulation of p53 by Mdm2 is a multifaceted process, the regulation of Mdm2 itself is 
complex. 
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In order to regulate p53, Mdm2 must first gain entry to the nucleus. The 
mechanisms governing the nuclear-cytoplasmic shuttling of Mdm2 are highly regulated 
and dependent on specific signaling conditions and timing. In response to MAPK 
activation by IGF-1, the PI3-kinase activates Akt/PKB, which in turn phosphorylates 
Mdm2 at S166 and S186 [30]. These serines are proximal to the nuclear localization 
sequence on Mdm2, and phosphorylation of these sites causes rapid translocation of 
Mdm2 to the nucleus and Mdm2-mediated inhibition of p53 [30]. Interestingly, IGF-1 
stimulation of MAPK can also lead to the nuclear export of Mdm2. The downstream 
kinase of MAPK, p90Rsk, phosphorylates Mdm2 in response to IGF-1 and causes 
nuclear export of Mdm2 [31]. While the IGF-1/MAPK/PI3K/Akt pathway results in rapid 
translocation of Mdm2 to the nucleus in under five minutes, the IGF-1/MAPK/p90Rsk 
pathway acts more slowly and results in export of Mdm2 from the nucleus at around 30 
minutes [30, 31]. ATR has also been shown to prevent p53 nuclear export by 
phosphorylating Mdm2 at S407 in response to DNA damage [32]. p19ARF is another 
protein that interacts with Mdm2 to block the Mdm2-mediated degradation of p53. The 
exact mechanism of p19ARF inhibition of Mdm2 is not known, but it is clear that p53 is 
stabilized by blocking the nuclear-cytoplasmic shuttling of Mdm2 [33, 34]. It seems that 
in this context, Mdm2 is stuck in the nucleus by being linked to the nucleolus by p19ARF 
[35]. Another mechanism of both p53 stabilization and Mdm2 degradation is governed by 
PTEN. Like MDM2, PTEN is a target of p53 but is induced in response to apoptosis 
where the MDM2 gene is not induced. PTEN is capable of inhibiting the PI3K/Akt 
pathway, which leads to decreased nuclear Mdm2 and increased cytoplasmic Mdm2. 
When Mdm2 is restricted to the cytoplasm it is degraded and has a reduced half-life [36]. 
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In this manner, PTEN causes an increase in p53 activity and p53 target genes resulting in 
a sensitization of cells to chemotherapy [36]. Mdm2 is also highly regulated at the 
promoter level, resulting in varied splice forms and transcript levels of MDM2 in 
response to different signaling pathways. 
 There are two promoter regions in the MDM2 gene. The P1 promoter is constantly 
activated, but the P2 promoter contains binding sites for p53. In response to DNA 
damage, p53 is stabilized and activated and it binds to the P2 promoter of MDM2 to 
promote its transcription [15, 37]. While the P1 promoter is basally active, it has been 
shown that p53 only binds to the P2 promoter in response to stress [38]. Elevated Mdm2 
protein then destabilizes p53 either by directly blocking its transcription or through 
ubiquitination and subsequent degradation. While p53 activation of the P2 promoter feeds 
into the autoregulatory feedback loop, there are other ways in which the P2 promoter can 
be activated. In response to TGF-b1 signaling, the Smad3/4 transcription factors bind to 
the P2 promoter of MDM2 and activate its transcription [39]. In recent years, many other 
mechanisms of both activating and inhibiting MDM2 transcription have been identified. 
In ER+ breast cancer cells, ETS2 is able to bind to an AP1-ETS responsive element to 
activate transcription of MDM2 [40]. MDM2 can also be activated by Vitamin D, thyroid 
hormone receptor, and estrogen, while retinoic acid can inhibit MDM2 transcription [41-
45]. 
In addition to the ubiquitinating function of Mdm2 in response to genotoxic 
stress, it has recently been shown that Mdm2 is also able to function as an E3 nedd8 
ligase, which was later shown to be in response to phosphorylation by the tyrosine kinase 
c-Src [46, 47]. Mdm2 can then neddylate p53, but rather than causing degradation as in 
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the case of ubiquitination, neddylation actually increases the stability of p53, but it is 
inactive [47]. A related protein to Mdm2, MdmX (also known as Mdm4), is important for 
Mdm2 mediated ubiquitination and neddylation as it forms a dimer with Mdm2 in order 
to effectively inhibit p53 [48]. Additionally, MdmX is able to bind directly to p53 to 
inhibit its tumor suppressive function independently of Mdm2 [49]. The fact that MdmX 
can inhibit p53 independent of Mdm2 highlights the fact that there are many other protein 
interactions in the p53-Mdm2 pathway that can either stabilize or destabilize p53. For 
instance, problems in the retinoblastoma signaling pathway during cell division can result 
in increased transcription of the ARF gene. The ARF protein is an inhibitor of Mdm2, 
which allows p53 protein levels to increase and causes cell cycle arrest or apoptosis to fix 
or discard damaged cells [50-52]. While p53 is the most studied target for Mdm2/MdmX 
mediated ubiquitination and neddylation, there are other targets of the E3 ligase as well, 
such as the promoter of cellular invasion Slug [53]. These target proteins have opened the 
door for p53-independent functions of Mdm2 to be explored.  
1.3 The p53-independent roles of Mdm2 in cancer 
1.3.1 Introduction 
 Mouse double minute 2 (Mdm2) was first cloned in 1987 from a transformed 3T3 
double minute mouse cell line [54].  There were three copies of the gene termed Mdm1, 2 
and 3.  The second copy was able to transform murine cells with Ha-Ras [54-56].   
Furthermore, the human homologue of Mdm2, Hdm2, was able to transform human cells 
with Ha-RasV12 and the E1A viral oncogene [57]. The protein encoded by the MDM2 
gene is elevated in 40-80% of human tumors [39]. The most studied role of Mdm2 is its 
downregulation of the tumor suppressor p53. Mdm2 binds and mono-ubiquitinates p53 in 
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the nucleus in response to DNA damage, leading to the nuclear export and subsequent 
degradation of p53 [14, 17, 19-22, 37]. The primary reason that this role is considered to 
be the most prominent role of Mdm2 is due to the fact that knockout of p53 rescues an 
embryonic lethality of mdm2-/- mice [58, 59]. Embryonic lethality of mdm2-/- mice 
occurs at 6.5 days post coitum (dpc), as Mdm2 plays important roles in the development 
of many tissue types. At 10.5 dpc, Mdm2 is ubiquitously expressed, but by 12.5 dpc the 
expression is tissue specific. Interestingly, at 18.5 dpc Mdm2 is expressed in the retina, 
where tumors are commonly found with defects in the retinoblastoma protein that Mdm2 
is able to regulate [60]. This study led many to believe that the regulation of p53 was the 
only important role of Mdm2, and much of the literature is focused on Mdm2 in the 
context of its regulation of p53. However, Mdm2 has been studied for its oncogenic 
effects in many different types of cancers, including those harboring mutations or 
deletions in p53. Jones et al. were the first to definitively show that Mdm2 had tumor-
promoting effects independently of p53. Using a transgenic mouse model that globally 
expressed high amounts of mdm2 mRNA they showed that increased expression of mdm2 
led to an increased incidence of tumor formation, regardless of p53 status [61]. Since this 
groundbreaking study, Mdm2 has been shown to be involved in a plethora of cellular 
processes that are independent of p53. Mdm2 can disrupt the normal cell cycle [62-69],  
slow down DNA repair processes [70, 71], increase invasiveness and migration of tumor 
cells [43, 72-76], and cause cellular transformation [43, 61, 77, 78] all in the absence of 
functional p53.  
 It is abundantly clear that Mdm2 can regulate p53. The emergence of so many 
functions of Mdm2 that occur in the absence of p53 raises the question of what the main 
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role of Mdm2 is in a tumor setting. It is possible that Mdm2 is able to affect the same 
proteins and pathways both dependent on and independent of p53, but that the laws of 
physics are followed and Mdm2 takes the path of least resistance. Alternatively, specific 
signaling pathways may dictate the activity of Mdm2 and it cellular substrates dependent 
on extracellular or intracellular cues.  As described by Hanahan and Weinberg, there are 
ten hallmarks of cancer [79]. Currently, Mdm2 is integrated into five of these hallmarks 
independently of p53 (Figure 1).  
1.3.2 Mdm2 in tumorigenesis 
After the discovery of the TP53 gene it quickly became clear that its protein 
product, p53, was important in the regulation of the cell cycle and apoptosis (reviewed in 
[80]). After the identification of p53, there was an obvious desire to identify and 
characterize other proteins that interact with and regulate p53. Momand et al. found that a 
90 kDa protein precipitated with p53 and that this 90 kDa protein was able to form a 
stable complex with p53 in vivo. Further characterization showed that the 90 kDa protein 
was the protein product of the MDM2 gene [14]. In their analysis, the authors saw that 
not all p53 was bound by Mdm2 and so they wanted to determine if the same was true of 
Mdm2. Using a similar approach, they investigated the amount of free p53 and free 
Mdm2 in cells with well-known growth characteristics. In every cell line that they tested, 
there was a fraction of Mdm2 that was not in complex with p53 [81]. Notably, in 3T3DM 
cells, which were the most tumorigenic cells that they tested, over 98% of total Mdm2 
was not bound to p53. In the same cells, there was no p53 found outside of complexes 
with Mdm2. While normal cell lines tested also had high levels of free Mdm2, this still 
raises the question of what the other 98% of Mdm2 protein is doing in tumor cells.   
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Figure 1. Mdm2 is involved in several hallmarks of cancer. Adapted from [79]. 
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To address the possibility of Mdm2 playing a role in transformation, a mouse 
model was made where several copies of the entire mdm2 gene under the control of its 
native promoter were integrated into the genome [61]. mdm2 mRNA and protein 
expression were verified and the mice were monitored for tumor development. Mice 
overexpressing Mdm2 were susceptible to tumor formation, and the rate of tumor 
formation was dose dependent on copies of the mdm2 pseudo-gene. Although the rate of 
tumor formation between p53-/- mice and p53-/-mdm2+/+ mice were almost identical, 
the types of tumors that developed were very different. p53-/-mdm2+/+ mice were much 
more likely to get sarcomas than p53-/- mice, suggesting that Mdm2 plays a role 
independent of p53 in the formation of tumors. In order to further investigate the role that 
Mdm2 plays in the development of tumors, Lundgren et al. developed a model in which 
MDM2 expression was regulated by the BLG promoter, which was induced in mammary 
glands during gestation and lactation [78]. In this model, increased Mdm2 caused a defect 
in cytokinesis in both p53 positive and p53 null mice. While S phase progressed as usual 
in these mice, cytokinesis did not occur, leading to large multinucleated cells. Mice that 
harbored Mdm2 overexpression also developed mammary tumors at a much faster rate 
than control animals.   
1.3.3 Mdm2 promotes an aggressive cell cycle 
 Progression through the cell cycle is an intricate process with many checkpoints 
in place to ensure the successful and error free replication of cells. In cancer, the cell 
cycle becomes dysregulated through many different mechanisms. Neoplastic cells are 
able to rapidly proliferate by abrogating certain checks during a normal cell cycle. By 
removing these checks, cancer cells can both grow rapidly and have a higher propensity 
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for further mutations since there is not as much time for DNA repair processes to take 
place. Mdm2 is able to influence the cell cycle through a number of mechanisms, through 
both direct interactions with p53 and by some mechanisms that are completely 
independent of p53.  
Perhaps the most significant way that Mdm2 can affect the cell cycle 
independently of p53 is through the Rb/E2F pathway. The tumor suppressor Rb binds 
many E2F transcription factors and inhibits their transcriptional activity, which is 
important for the cell cycle and apoptosis [82-84]. Mdm2 is able to overcome a blockage 
of the cell cycle by the tumor suppressor p107, an Rb family member [77]. p107 binds 
preferentially to E2F4 and causes cells to arrest in the G1 phase, inhibiting the growth of 
cells and allowing time for DNA repair proteins to function [85]. In the presence of 
Mdm2, and both with or without p53, the G1 arrest can be overcome in an Mdm2-
dependent manner. During the normal progression of the cell cycle, Rb becomes 
hyperphosphorylated by cyclin-dependent kinases (CDKs) and releases E2Fs. Mdm2 can 
bind directly to Rb, and release E2F1 to induce downstream genes. Interestingly, Mdm2 
binds preferentially to hypophosphorylated Rb, which would ordinarily inhibit E2F1 [68]. 
Also is it has been reported that Mdm2 could bind to E2F1 directly and activate the 
transcriptional activity of E2F1 [69]. Additional literature suggests that p53 directly 
regulates the transcription factor E2F1, independent of both Mdm2 and Rb [86]. 
However, most data points to Mdm2 having a direct impact on the inhibition of E2F1. 
For instance, one study showed that Mdm2 was able to downregulate E2F1 through a 
cascade of events initiated by the inhibition of p53 [67]. This may be a key pathway for 
the inhibition of apoptosis mediated by E2F.  Furthermore, the authors showed how 
13 
Mdm2 inhibition of p53 resulted in decreased levels of p21. Additionally, Mdm2 has 
been shown to increase the degradation of p21 independent of ubiquitination [87]. Since 
p21 inhibits the cyclins/CDKs responsible for hyperphosphorylation of Rb, lower levels 
of p21 result in more phosphorylation of Rb and a release of E2F. Interestingly, while 
these authors were investigating the role of Mdm2 on E2F1 signaling, they discovered 
that MdmX was also able to inhibit E2F1 independently of p53 [88]. This points to a 
prominent role of Mdm2 and MdmX in the Rb/E2F signaling pathway. Mdm2 has also 
been shown to bind to E2F1 and inhibit the SCFSKP2 ligase from ubiquitinating E2F1 
[69]. There are many ways in which Mdm2 alters the function of E2F1, but one 
intriguing mechanism is through DP1, which forms dimers with E2F1. E2F1 has 
transcriptional activity on its own, but its ability to bind DNA increases when it forms 
heterodimers with DP1. Separate labs have shown that Mdm2 interacts with DP1 [64, 
65]. In their model system, Mdm2 caused a defect in apoptosis only in the presence of 
DP1, suggesting that DP1 is the regulatory subunit for Mdm2 [64]. When Mdm2 was 
bound to DP1 there was a change in function of the E2F1/DP1 heterodimers from pro-
apoptotic to pro-growth. While one group was able to see an interaction with Mdm2 and 
E2F1 in vitro using recombinant proteins, they were not able to see the same interaction 
in cells [65]. Though they suggested that the lack of a detectable interaction may be due 
to low levels of E2F1 in their cells, it is possible that Mdm2 only interacts with DP1 or 
alterations in the post-translational modifications to either protein is necessary for the 
E2F interaction. One of the very early papers on E2F1/DP1 heterodimers showed that the 
adenovirus E4 protein was able to bind to DP1, but not E2F1, and increase the DNA 
binding capacity of the heterodimer [89]. An overview of the impact of Mdm2 on this 
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signaling pathway is shown in Figure 3. Mdm2 is also able to overcome a proliferative 
checkpoint after being induced by estrogen in Estrogen Receptor alpha (ER+) positive 
breast cancer cells [43]. The induction of Mdm2 by estrogen is independent of p53 and 
results in a more aggressive phenotype in response to estrogen. 
 Forkhead box proteins O3A and O1 (FOXO3A and FOXO1) are able to inhibit 
the cell cycle through varying mechanisms. Fu et al. were investigating possible crosstalk 
between the p53 pathway and the FOXO pathway when they noticed an inverse 
correlation in the protein levels of Mdm2 and both FOXO3A and FOXO1. They 
determined through several biochemical assays that Mdm2 bound to and mediated 
ubiquitination to the FOXO proteins [62]. While the authors suggest that ubiquitination 
of FOXO proteins by Mdm2 is dependent on p53, the reason was that p53 has the ability 
to transcribe Mdm2. Since it has been shown that Mdm2 protein levels can still be high in 
the absence of p53 and that Mdm2 can be transcriptionally activated in the absence of 
p53 [75, 90, 91], it is highly possible that the regulation of these FOXOs by Mdm2 is also 
a p53 independent event.  
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Figure 2. A map of the domains and interactions of the Mdm2 protein.  Regions where Foxo, E2F1, DP1, 
NBS1, Rb and RNA are designated in the specific domains. 
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1.3.4 Mdm2 inhibits the DNA damage response 
 One of the major reasons for checkpoints in the cell cycle is to allow for DNA 
damage to be repaired before cell division continues. This is one of the main defense 
mechanisms that cells have against cancer causing mutations. p53 is responsible for a 
large portion of the DNA damage response (DDR) by causing growth arrest, apoptosis, 
and DNA repair. Tumor suppression by p53 is accomplished through p53 functioning as 
a transcription factor for a wide variety of genes, and as mentioned above, is blocked by 
Mdm2 complexing with p53. In addition to the regulation of p53, Mdm2 has been found 
to have other effects on the DDR which are independent of p53. Namely, Mdm2 is 
associated with the Mre11/Rad50/Nbs1 (MRN) complex [70, 71].  
The MRN complex is important for repairing double strand DNA breaks (DSBs). 
Mre11 recognizes sites of DSBs and binds directly to the free ends of DNA. Rad50 is an 
ATPase and provides the energy for the complex, while Mre11 provides nuclease 
function. Nbs1 is localized to DSBs through binding to Mre11. Alt et al. demonstrated 
that Mdm2 is able to bind to Nbs1 at sites of DNA damage, but not to Mre11 or Rad50 
[70]. The authors showed that Mdm2 expression resulted in a delay in DNA repair that 
was independent of both p53 and ARF, but dependent on Nbs1. Another group published 
a similar study in which they showed that Mdm2 overexpression led to an increase in 
chromosome and chromatid breaks in addition to a delay in DNA repair dependent on 
Nbs1 [71]. This group mapped the Mdm2 binding domain for Nbs1 as amino acids 198-
228 of Mdm2, in between the nuclear export sequence (NES) and the acidic domain 
(AD). The binding region of Nbs1, as well as other binding regions of interest in this 
section, are seen in Figure 2.  
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Figure 3. Mdm2 impacts the Rb signaling pathway. The pathway shows how Mdm2 affects 
transcription of E2F1 target genes and how Mdm2 blocks Rb and SCF. 
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1.3.5 Mdm2 promotes metastasis 
 Mdm2 plays an important role in the conditioning of the tumor 
microenvironment. In order for a tumor to become metastatic, it must circumvent the 
cellular junctions to migrate away from the primary tumor and intravasate into the blood 
stream to travel through the circulatory or lymphatic system to reach a distant site. The 
first step in this process is traveling through the tissue immediately surrounding the 
tumor. There are many obstacles standing in the way of tumor cell invasion. Mdm2 is 
able to promote metastasis through many different mechanisms involving the secretion of 
matrix metalloproteinases [72, 92-94], degradation of cell-cell adhesion proteins [74], 
and stabilization of proteins involved in angiogenesis [76, 95-97].   
 Matrix metalloproteinase-9 (MMP-9) is an important regulator of the extracellular 
matrix (ECM). When activated, MMP-9 functions to digest type IV and V collagen in the 
ECM, making it easier for cells to travel through this dense space [94]. Multiple groups 
have shown that Mdm2 was correlated with the expression of MMP-9 in breast [72], 
pancreatic [93], and lung [92] cancers. Mdm2 expression was correlated with an increase 
in both mRNA and protein levels of MMP-9 [72]. In an animal model of lung cancer, the 
correlation between MMP-9 and Mdm2 was the highest in late stage tumors [92].  
In addition to the degradation of the ECM, Mdm2 has profound effects on vascularization 
in tumors in response to hypoxia. It is clear that Mdm2 and hypoxia-inducible factor 1 
alpha (HIF1a) bind directly to each other in response to hypoxia [95-100]. HIF1a is 
stabilized under hypoxic conditions and translocated to the nucleus, where it is free to 
bind to its partner protein HIF1b. This heterodimeric protein complex is important for 
activating the transcription of several target genes important for cell survival and the 
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hypoxic response. Interestingly, there is also a slight increase in Mdm2 protein in 
response to hypoxia that is independent of p53 [97]. There is some controversy in these 
studies regarding what the role of Mdm2 is under hypoxia, possibly stemming from the 
different conditions these groups consider hypoxia. However, the majority of the 
available data points to Mdm2 stabilizing HIF1a in response to hypoxia, which in turn 
causes an increase in the transcription of vascular endothelial growth factor (VEGF) [97]. 
VEGF is one of the major target genes for HIF1a, and it is a crucial regulator of 
angiogenesis. In addition to activating the transcription of VEGF through the stabilization 
of HIF1a, Mdm2 is also able to bind directly to the 3’ UTR of VEGF mRNA and 
increase its stability and protein levels [76].  
 There have been many mechanistic studies showing that Mdm2 increases the 
metastatic potential of cancers, but the most convincing data comes from studies of 
human tissue samples. High levels of Mdm2 correlate with metastasis and late-stage 
tumors in both breast cancer and melanoma [39, 73]. Recent work from our own lab has 
shown that Mdm2, and not gain of function mutant p53, is required for the early stages of 
metastasis [101]. This research has been verified by another group, who recently showed 
that both Mdm2 and MdmX can promote metastasis in TNBC [102]. The intricate roles 
that Mdm2 plays in metastasis are not fully understood, but these studies provide a clear 
rationale for the continuation of studies that investigate Mdm2 in metastasis. 
1.3.6 Conclusion 
 Ever since the initial cloning and identification of Mdm2, the focus of subsequent 
studies has been shackled by its interaction with p53. The overwhelming majority of 
research surrounding Mdm2 is still centered around its regulation of p53. While the 
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interaction with p53 is undoubtedly a role for Mdm2, it is clearly not its only function. In 
addition to p53, there are many other transcription factors that are able to activate 
transcription of the MDM2 gene [75, 90, 91]. Since tumor cells have evolved mechanisms 
to turn on Mdm2 in the absence of p53, there must be an advantage for tumor cells to 
have high levels of Mdm2. The last decade has seen an increase in the interest of p53-
independent effects of Mdm2. This is highly relevant given the immense interest in 
targeting the Mdm2/p53 interaction to treat cancers. Until the p53-independent effects are 
better understood these treatments will likely continue to be compromised. Only through 
the complete study of Mdm2’s interacting proteins and the ways in which the MDM2 
gene can be activated will we be able to effectively target this pathway as a cancer 
treatment. 
1.4 The canonical VHL-HIF pathway 
The hypoxia inducible factors (HIFs) are dimeric protein complexes responsible 
for the cellular response to low oxygen. They function as transcription factors to turn on 
genes with hypoxia responsive elements (HREs) that impact a variety of cellular 
functions including angiogenesis, metabolism, growth, and migration [103]. There are 
three hypoxia inducible factor a subunits – HIF1a, HIF2a, and HIF3a. HIF1a is highly 
conserved across species and is thought to be the major driver of the hypoxia response. 
HIF2a has some overlapping functions with HIF1a, but differs in that it regulates 
erythropoietin production in adults [103]. HIF3a has complementary and inhibitory 
functions to HIF1a and HIF2a, but is less well understood. Recent studies suggest that 
HIF3a may actually inhibit HIF1a and HIF2a in the inflammatory and hypoxic 
responses [104-106]. 
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Under normal oxygen, HIF1a and HIF2a subunits are hydroxylated by various 
prolyl hydroxylases (PHDs) at Pro402/564 and Pro405/531, respectively [107-109]. This 
prolyl hydroxylation allows the von Hippel-Lindau (VHL) protein to recognize these 
HIFa subunits and target them for degradation via the 26S proteasome [108-111]. VHL 
serves as the substrate recognition protein in a ubiquitin E3 ligase complex along with 
elongin B, elongin C, Cul2, and Rbx1 [110, 112]. In low oxygen conditions the PHDs are 
inactive due to lack of oxygen, which stabilizes HIFa subunits. HIF1a is most active in 
acute (less than 24 hours) or severe (less than 0.1% O2) hypoxia while HIF2a is more 
active under chronic (48-72 hours) or mild (less than 5% O2) hypoxia [113, 114]. 
Stabilized HIFa subunits move into the nucleus to bind with their ubiquitously expressed 
HIFb/ARNT subunits to activate transcription [115, 116]. 
Pathogenic disruption of VHL/HIFa regulation can be hereditary or spontaneous. 
In VHL Disease, patients inherit a mutated form of VHL that causes a variety of clinical 
presentations depending on the specific mutation [117-120]. Many, but not all of these 
mutations have a defect in HIFa binding, which directly relates to the severity of the 
clinical presentation (Table 1) [121]. Approximately 1 in every 35,000 live births is 
diagnosed with VHL Disease, and there are over 150 identified germline mutations [120, 
122]. These mutations are categorized based on their clinical presentation into Type 1, 
Type 2A, Type 2B, or Type 2C. Examples of Type 1 VHL Disease include a complete 
deletion of the VHL gene or a C162F point mutation. The C162F mutation results in a 
mutant VHL that has reduced binding to both HIF1a and elongin C and loses its ability 
to regulate HIFa [111]. Type 2A mutants, such as Y98N and Y112H, have also lost their 
ability to regulate HIFa, but they present with a low risk for renal cell cancer [123]. Type 
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2B mutants, such as R167Q, are able to regulate HIFs, but still present with a high risk 
for renal cell cancer [124]. The R167Q mutant has a reduced ability to bind to elongin C, 
but maintains binding to elongin B, Cul2, and Rbx1. While controversial, it appears that 
VHL R167Q has a reduced half-life as compared to WT VHL and its ability to regulate 
HIF2a is slightly impaired [125]. VHL mutations that result in Type 2C VHL Disease, 
such as L188V and K159E, maintain their ability to fully regulate HIF1a and present 
only with pheochromocytoma [111, 126]. Additionally, VHL is commonly mutated in 
spontaneous renal cell carcinoma [117, 127, 128]. These tumors are highly vascularized 
and have high expression of HIF protein and gene expression of HIF targets.   
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VHL Disease 
Type Clinical Presentation Mutations 
HIF 
status 
Type 1 
RCC, retinal angioma, CNS 
hemangioblastoma, pancreatic cysts, 
neuroendocrine tumors, low risk for 
pheochromocytoma 
Truncating 
or missense ­­­ 
Type 2A Pheochromocytoma, retinal angioma, CNS hemangioblastoma, low risk for RCC Missense ­ 
Type 2B 
Pheochromocytoma, retinal angioma, CNS 
hemangioblastoma, pancreatic cysts, 
neuroendocrine tumors, high risk for RCC 
Missense ­­ 
Type 2C Pheochromocytoma only Missense Normal 
Table 1. VHL Disease types. Information obtained from [121]. 
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2. Materials and Methods  
2.1 Cell culture 
 All cell lines were cultured in Dulbecco’s modified Eagle medium with 8-10% 
fetal bovine serum and supplemented with penicillin and streptomycin in a 37° C 
humidified incubator in 5% CO2. Anisomycin, SP600125, and camptothecin were 
purchased and suspended as described by the manufacturer (Sigma-Aldrich). Anisomycin 
was used at 30 µM, camptothecin was used at 30 µM, and SP600125 was used at 25 µM 
unless otherwise noted. For hypoxia experiments, cells were cultured in DMEM/F12 1:1 
and placed at 37° C in a humidified incubator with 1% O2 in a BioSpherix SubChamber 
System with a ProOx oxygen controller. 
2.2 Transient transfection 
Transient transfections were performed using polyethylenimine at 1:1 with DNA. 
Annexin V and Dead Cell Assay kit from Millipore was used to stain cells that were 
analyzed on a Muse cytometer. 
2.3 Plasmid generation 
We generated the mutant p53 plasmids using the p53-SN3 plasmid with a site 
directed mutagenesis kit (Life technologies). The oligonucleotides for these mutations are 
shown in Table 2. Following mutagenesis in p53-SN3, the p53 gene was subcloned into 
either pRSET A or pNIT (LNITX) using BamH1.   
25 
T81E forward 5’-CCAGCAGCTCCTGAACCGGCGGCC-3’ 
T81E reverse 5’-GGCCGCCGGTTCAGGAGCTGCTGG-3’ 
T81A forward 5’-CCAGCAGCTCCTGCACCGGCGGCC-3’ 
T81A reverse 5’-GGCCGCCGGTGCAGGAGCTGCTGG-3’ 
S46D forward 5’-GATTTGATGCTGGACCCGGACGATATTG-3’ 
S46D reverse 5’-CAATATCGTCCTGGGCCAGCATCAAATC-3’ 
Table 2. Oligonucleotides used for the site directed mutagenesis of p53. 
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2.4 Protein purification 
Recombinant proteins (p73, p53, GST, GST-alpha VHL, GST-beta VHL, GST-
VHL, His-Mdm2, and GST-p300 HAT domain) were produced in BL21DE3 cells and 
purified as previously described [129, 130]. His-Src was purchased from Millipore and 
the neddylation reaction components were purchased from Boston Biochem. 
2.5 Far Western and Western blotting 
Far Western was completed by 96 well dot blot system and recombinant proteins 
were placed in wells and fixed to nitrocellulose by drying.  Blot was blocked with 5% 
nonfat dry milk and incubated with recombinant p73. p73 was then detected by p73 
antibody followed by secondary and an enhanced chemiluminescence (ECL) reagent.  
Western blot analysis used whole cell lysates lysed with Urea Lysis Buffer or 
immunoprecipitated proteins extracted with IP Lysis Buffer (Table 5).  Whole cell 
lysates, immunoprecipitated proteins, pulldown assays, and in vitro reactions were all 
subjected to SDS-PAGE and transferred to PVDF membrane. Western blots for all 
antibodies were performed according to the manufacturers’ protocols (Table 3). 
2.6 I-TASSER protein structure prediction 
Amino acid sequences for wild-type p53, R248W p53, T81E p53, S46D, and 
R248W/T81E p53 were input to the I-TASSER web server as FASTA sequences. Predicted 
protein structures were generated using a previously described method [131-133] and 
analyzed using the CCP4 Molecular Graphics Program (CCP4MG) v. 2.10.6 [134]. 
Structures were superposed using a built in function within the software. 
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Cell Line p53 status VHL status Notes 
H1299 Null Wild type Used for 
transfections 
TMD231 R280K Wild type Derivative of 
MDA-MB-231 
U87 Wild type Wild type  
HME1 Wild type Wild type  
SF767 Wild type Wild type  
3T3 Wild type Wild type Mouse cell line 
hTERT BJ Wild type Wild type  
MDA-MB-468 R273H Wild type  
MDA-MB-157 A88fs*52 Wild type  
786-O P278A/WT G104fs p53 status is 
contested - 
data suggests it 
could be wild 
type. 
RCC4 Wild type Null  
Caki-1 Wild type Wild type  
MCF7 Wild type Wild type  
GFP HUVEC Wild type Wild type  
Table 3. Description of cell lines used. Data obtained from the Cancer Cell Line Encyclopedia. 
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Target Clone Company Concentration Data Type 
Actin C4 SCBT 1:5,000 WB 
BAX 2D2 SCBT 1:1,000 WB 
GST  SCBT 1:5,000 WB 
HA 12CA5 Roche 1:1,000 
2 µg/sample 
WB 
IP 
HIF1a H1a67 SCBT 1:1,000 WB 
His HIS.H8 Thermo 1 µg/sample Pulldown 
JNK D-2 SCBT 1:1,000 WB 
pJNK 9251 CST 1:1,000 WB 
Mdm2 IF2 Millipore 1:500 
2 µg/sample 
WB 
IP 
Mdm2 2A10  1:2,000 WB 
Mdm2 2A9  1:2,000 WB 
Mdm2 4B2  1:2,000 WB 
Nedd8 A-812 R&D 1:1,000 
2 µg/sample 
WB 
IP 
Ac-p53 K373/382 06-758 Millipore 1:1,000 WB 
p53 DO-1 SCBT 1:4,000 
2 µg/sample 
1:100 
1:10,000 
WB 
IP 
IF 
Far Western 
p53 FL-393 SCBT 1:1,000 
2 µg/sample 
WB 
IP 
p-p53 T81 2676 CST 1:1,000 WB 
p73 D3G10 CST 1:1,000 
1:100 
WB 
IF 
p73 Ab-1 Millipore 1:500 
2 µg/sample 
1:5,000 
WB 
IP 
Far Western 
p73 Ab-2 Millipore 1:500 
2 µg/sample 
1:5,000 
WB 
IP 
Far Western 
PUMA  CST 1:500 WB 
TSP-1 A6.1 SCBT 1:500 
100 ng/sample 
Dot Blot 
Tube forming 
VHL VHL40 SCBT 1:1,000 
2 µg/sample 
1:100 
WB 
IP 
IF 
VHL FL-181 SCBT 1:1,000 WB 
VHL IgG 32 BD 2 µg/sample IP 
VHL S2-647 BD 1:2,000 WB 
VHL NBP2-30070 Novus 1:2,000 WB 
Table 4. List of primary antibodies 
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2.7 Immunofluorescence microscopy 
MDA157, HME, or TMD231 cells were grown on glass coverslips. 786-O, 
RCC4, or Caki-1 cells were grown on glass coverslips and transfected with WT or 
K159E VHL. Following transfection for 24 hours, cells were treated with MLN4924 or a 
control for an additional 16 hours. Cells were fixed in 4% paraformaldehyde in phospho-
buffered saline (PBS) for 15 minutes, washed with PBS, and permeabilized in 1% Triton 
X-100 in PBS for 15 minutes. Coverslips were blocked in 5% bovine serum albumin for 
1 hour in PBS/Tween before being stained with the indicated antibodies. Coverslips were 
then incubated with anti-rabbit AlexaFluor 647 and anti-mouse AlexaFluor 488 
secondary antibodies before being fixed to slides with ProLong Diamond Antifade 
Mountant with DAPI (Life Technologies). Slides were visualized on a Leica SP8 MP 
microscope. Colocolization analysis was done using Imaris v9.0.2 and colocalized 
images were created using the “RG2B_Colocolization” plugin for ImageJ. Scale bar, 25 
µm (MDA157, TMD231) or 50 µm (HME).  
2.8 Colony forming assay 
Empty Vector and shp53 hTERT BJ cells where plated in triplicate and treated 
with Anisomycin for 9 hours. Dimethyl sulfoxide (DMSO) was used as a vehicle control. 
Cells were stained with equal parts methanol and methylene blue for 15 minutes. The 
plate was then washed 3 times with deionized water to remove any excess stain and left 
to dry at room temperature. 
2.9 GFP fluorescence assay 
 Green fluorescent protein (GFP) shp53 and LVTHM Empty Vector control BJ 
cells were plated in quadruplet and treated with DMSO or 10 µM of Anisomycin for 48 
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hours. Fluorescence emitted by GFP in each well was measured at 509 nm using a 
SpectraMax M5 spectrophotometer (Molecular Devices). 
2.10 Thrombospondin-1 reporter assay 
 H1299, 786-O, RCC4, or Caki-1 cells were transfected with a reporter construct 
for thrombospondin-1 as previously described [47]. Luciferase activity was measured 
following transfection for 40 hours, with 16 hours of MLN4924 when noted in the figures 
(Table 4). 
2.11 Secreted thrombospondin-1 assay 
 786-O or RCC4 cells were cultured in DMEM for 48 hours. Media was harvested 
and passed through a nitrocellulose membrane using a Bio-Dot microfiltration apparatus 
(BioRad). The membrane was then incubated with an antibody for TSP-1 (A6.1, Santa 
Cruz) and analyzed by Western blot. Resulting images were quantified using the Dot Blot 
Analyzer plugin for ImageJ. 
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Reagent Catalog Number Company 
Angiogenesis Array ARY007 R&D Systems 
Anisomycin A9789 Sigma-Aldrich 
Camptothecin C9911 Sigma-Aldrich 
GFR Matrigel 354230 Corning 
Luciferase Assay Substrate E1501 Promega 
Luciferase Control T1056 Invitrogen 
MLN4924 SI9830 Life Sensors 
Mouse 2° Antibody AlexaFluor 488 A28175 Invitrogen 
Mouse 2° Antibody HRP 1706516 BioRad 
Ni-NTA Agarose 30210 Qiagen 
Nedd8 UL-812 Boston Biochem 
Nedd8 E1 E-312 Boston Biochem 
Nedd8 E2 E2-656 Boston Biochem 
p53 shRNA Sc-29435 Santa Cruz 
PP1 956025-83-5 Calbiochem 
ProLong Diamond Antifade Mountant with 
DAPI 
P36962 Thermo Fisher 
Protein G Agarose 20398 Pierce 
Rabbit 2° Antibody AlexaFluor 647 A27040 Invitrogen 
Rabbit 2° Antibody HRP 1706515 BioRad 
SP600125 S5567 Sigma-Aldrich 
Src Kinase 14-326 Millipore 
TSP-1 ELISA Kit ELH-TSP1-1 Ray Biotech 
Table 5. List of miscellaneous reagents 
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2.12 Generation of shp53 786-O and RCC4 cell lines 
 Lentiviruses encoding shRNA to p53 or a control were transfected in 293 phoenix 
cells. Supernatant media containing virus was collected at 48 hours, supplemented with 
10 µg/mL polybrene, and syringe filtered through a 0.45 µm filter. Media containing 
virus was added to cells for 48 hours. Transduced cells were selected for by the addition 
of 2 µg/mL puromycin for one week. 
2.13 Enzyme-linked immunosorbent assay 
 H1299 cells were transfected according to figure labels using polyethylenimine 
for 24 hours, followed by 21% or 1% O2 culturing for 24 hours. 786-O and RCC4 cells 
were cultured in 21% or 1% O2 for 24 hours. All media was harvested and analyzed using 
an ELISA kit for TSP-1 (Ray Biotech) with a 10% dilution of conditioned media. 
2.14 Immunoprecipitation 
 Following transfection and/or treatment as described, cells were lysed in IP Lysis 
Buffer with protease inhibitor and 20 mM N-ethylmaleimide and incubated for 2 hours at 
4° C with Protein-G agarose beads which had been pre-incubated with antibody. 
Following incubation, beads were washed 3x with IP Wash Buffer for 10 minutes at 4° C 
(Table 5). After the final wash, 6X Lamelli dye was added to the beads and samples were 
boiled for 10 minutes at 100° C and separated with SDS-PAGE. 
2.15 GFP HUVEC tube formation assay 
 H1299 cells were transfected according to the figure panels for 48 hours followed 
by harvest. 786-O and RCC4 cells were cultured in 21% or 1% O2 for 48 hours followed 
by harvest. Growth factor reduced matrigel (Corning) was plated in a 96-well plate and 
allowed to set according to the manufacturer’s guidelines. GFP+ Human Umbilical Vein 
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Endothelial Cells were plated on top of the matrigel in 10% EBM-2/EGM-2 (Lonza) and 
90% conditioned media. Images were taken and analyzed using an Incucyte by Essen 
BioScience. 
2.16 Bioinformatics analysis of clinical data 
 Data was analyzed from KIRC_TCGA_PUB downloaded from cbioportal.org. 
Only samples with wild-type p53 were included. 62 samples with alpha domain 
mutations in VHL were included and 72 samples with wild type VHL were included.  
2.17 His-nedd8 pulldown 
 H1299 cells were transfected with His-nedd8 and other plasmids as shown in the 
figure panels. 24 hours after transfection, cells were treated with MLN4924 or a control 
for an additional 16 hours. Cells were lysed in denaturing conditions with Nickel 
Pulldown Lysis Buffer (Table 5) and sonicated. Lysates were incubated with 30 µL Ni2+-
NTA beads (Qiagen) for 2 hours at 4° C with rotation. The beads were washed and eluted 
with Nickel Pulldown Wash 1-4 and eluted with Nickel Pulldown Elution (Table 5) and 
subjected to SDS-PAGE. 
2.18 In vitro neddylation assay 
 500 ng of GST-VHL was incubated with 1 µg of His-Mdm2, 30 µM nedd8 
(Boston Biochem), 200 nM E1 (APPBP1/UBA3, Boston Biochem), 0.5 µM E2 (UbcH12, 
Boston Biochem), and 1.25 mM ATP in Neddylation Reaction Buffer (Table 5) at 37° C 
for one hour followed by SDS-PAGE. 
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Buffer Components pH 
Urea Lysis Buffer 6 M              urea 
20 mM         Tris-HCl 
100 mM       Na2HPO4/NaH2PO4 
6.8 
IP Lysis Buffer 25 mM         Tris-HCl 
150 mM       NaCl 
1%                IGEPAL 
1%                protease inhibitor cocktail 
1 mM           Na3VO4 
10 mM         NaF 
1 µM            Sodium Pyrophosphate 
20 mM         N-ethylmaleimide 
8.0 
IP Wash Buffer 25 mM         Tris-HCl 
150 mM       NaCl 
1%               IGEPAL 
8.0 
Nickel Pulldown Lysis Buffer 6 M              guanidinium-HCl 
100 mM       Na2HPO4/NaH2PO4 
10 mM         Tris-HCl 
5 mM           Imidazole 
10 mM         b-mercaptoethanol 
8.0 
Nickel Pulldown Wash 1 6 M              guanidinium-HCl 
100 mM       Na2HPO4/NaH2PO4 
10 mM         Tris-HCl 
10 mM         b-mercaptoethanol 
8.0 
Nickel Pulldown Wash 2 8 M              urea 
100 mM       Na2HPO4/NaH2PO4 
10 mM         Tris-HCl 
10 mM         b-mercaptoethanol 
8.0 
Nickel Pulldown Wash 3 8 M              urea 
100 mM       Na2HPO4/NaH2PO4 
10 mM         Tris-HCl 
10 mM         b-mercaptoethanol 
0.2%            Triton X-100 
6.3 
Nickel Pulldown Wash 4 8 M              urea 
100 mM       Na2HPO4/NaH2PO4 
10 mM         Tris-HCl 
10 mM         b-mercaptoethanol 
0.1%            Triton X-100 
6.3 
Nickel Pulldown Elution 200 mM       Imidazole 
5%               SDS 
150 mM       Tris-HCl 
30%             Glycerol 
720 mM       b-mercaptoethanol 
6.7 
Table 6. Description of buffers used 
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Buffer Components pH 
Neddylation Reaction Buffer 50 mM         Tris-HCl 
150 mM       NaCl 
2.5 mM        MgCl2 
7.6 
5X Acetylation Reaction 
Buffer 
250 mM       Tris-HCl 
50%             Glycerol 
0.5 mM        EDTA 
5 mM           DTT 
8.0 
Table 6. Description of buffers used, continued 
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3. Mutant and wild-type p53 form complexes with p73 upon phosphorylation by the 
kinase JNK 
3.1 Introduction  
The transcription factor family comprising p53, p63, and p73 control the 
induction of apoptosis in response to cellular stress and developmental cues. The three 
proteins have distinct as well as overlapping and interdependent functions. Mutations in 
p53 are common in human tumors; gain-of-function p53 mutants have a dominant-
negative effect on wild-type p73 by binding it and inhibiting its ability to bind DNA and 
thereby preventing its transcriptional induction of apoptotic genes [135, 136].  In mice, 
knockout of one or both alleles of the individual genes encoding p53, p63, or p73 resulted 
in reduced cell death in response to DNA-damaging stimuli [137], indicating that all three 
proteins are necessary to invoke a robust apoptotic response. However, whereas wild-
type p63 and p73 form heterodimeric (or higher order) complexes, wild-type p53 
reportedly does not [5, 138].   
  Wild-type p53 has two transactivation domains: TAD1 (amino acids 1-40) and 
TAD2 (amino acids 43-54). TAD2 is located proximal to the proline-rich domain (PRD; 
amino acids 63-97) [139, 140], and both TAD2 and the PRD are critical for p53’s 
induction of apoptotic genes [141, 142], whereas TAD1 is reportedly dispensable for this 
function [143].  Key phosphorylation sites responsible for the induction of apoptotic 
genes are contained within the PRD (Threonine 81) and TAD2 (Serine 46) [144-148]. 
Several kinases, such as HIPK2 and p38, reportedly phosphorylate Ser46 [144, 149, 150], 
and c-Jun N-terminal kinase (JNK) phosphorylates Thr81 [151], yet precisely how 
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modification of Thr81 regulates p53 activity in the context of apoptosis induction is 
limited.  
 The PRD is an important structural domain; prolyl isomerization in this domain 
regulates the structure of other domains of p53 [152]. Additionally, the PRD is necessary 
for growth suppression and apoptosis [153, 154]. From the literature, we rationalized that 
phosphorylation within the PRD may also be sufficient to alter the structure of other 
domains in p53 and thereby regulate its functional interactions. Our findings support 
previously published work on genetic knockout mice, the PRD, and mutant p53/p73 
complex formation [135, 136], but refine our current understanding of the interaction 
between wild-type p53 and p73. 
3.2 The phosphorylation of p53 by JNK results in the induction of the apoptotic protein 
PUMA 
Because JNK is a key inducer of p53-mediated apoptosis, and JNK 
phosphorylates p53 at Thr81, we were first curious whether Thr81 was phosphorylated in 
mutant p53 in cells. In MDA-MB-468 cells, which have a missense mutation in p53 
(R273H), TMD231 cells, which have a missense mutation in p53 (R280K), and MDA-
MB-157 cells, which have a truncation mutation in p53 (A88fs*52), JNK was activated, 
as determined by immunoblotting with antibodies against phospho-Tyr183/Tyr185 JNK 
(Figure 4).  In addition, mutant p53 was phosphorylated at Thr81 in cells cultured in 
growth-supporting conditions. Treatment with the DNA topoisomerase inhibitor 
camptothecin or the protein synthesis inhibitor anisomycin increased phosphorylation of 
JNK and phos-Thr81. In various cells that have wild-type p53, namely untransformed cell 
lines NIH3T3 (mouse fibroblast) and HME1 (human mammary epithelial), as well as 
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human foreskin fibroblast BJ cells and glioblastoma cell lines U87 and SF767, exhibited 
limited activation of JNK and phosphorylation of p53-Thr81 under growth conditions, 
but robust induction of both upon camptothecin or anisomycin exposure (Figure 5A). 
Thus in “normal” cells and tumor cells, JNK is activated and p53 (wild-type or mutant) is 
phosphorylated at Thr81 in response to cell stress.  
We then examined the dependence of JNK activation on the induction of PUMA, 
the apoptotic downstream target of p53. PUMA abundance was increased by anisomycin 
treatment in cells that had wild-type p53 (Figure 5B). However, the induction of PUMA 
was blocked by pretreatment with the small molecule JNK inhibitor SP600125, thereby 
confirming that activation of JNK was important for induction of the p53 target PUMA. 
Alongside this increase in PUMA abundance was a significant increase in cell death by 
~11-fold, thereby confirming the functional outcome of the pathway (Figure 6). 
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Figure 4. Phosphorylation of Thr81 of mutant p53 in response to JNK activation. (A) Western blot of 
phosphorylated JNK, phosphorylated Thr81 of p53, and actin in cellular extracts from TMD231, MDA-
MB-468 and MDA-MB-157 cells treated with either camptothecin or anisomycin for the indicated times. 
Blots are representative of three independent experiments. From [1]. Reprinted with permission from 
AAAS. 
40 
 
Figure 5. Phosphorylation of Thr81 of wild type p53 in response to JNK activation. (A) Western Blot of 
phosphorylated JNK or Thr81 of p53 and actin from cellular extract of 3T3, SF767, HME-1, BJ and U87 
treated with anisomycin or camptothecin for the indicated times. Blots are representative of three 
independent experiments. (B) Experiments performed by Kristen Bredhold and Amber Kline. U87 or 
SF767 cellular extracts from DMSO, SP600125, anisomycin or pretreatment with SP600125 then 
anisomycin, and western blotted for PUMA and actin. Blots are representative of two independent 
experiments. From [1]. Reprinted with permission from AAAS. 
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Figure 6. U87 cell death. Experiment performed by Kristen Bredhold. U87 cells were treated with 30 µM 
camptothecin for 6 hours or pretreated with 25 µM SP600125 for one hour and then treated with 30 µM 
camptothecin for 6 hours. Cell death was determined by flow cytometry using Annexin V. Error bars 
represent standard deviation from the mean; P values determined by a two-tailed unpaired t-test. From [1]. 
Reprinted with permission from AAAS. 
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3.3 The predicted structure of a Thr81 phosphomimic shows a potential mode of 
binding to p73 
 To gain insight into the structural implications of phosphorylation at Thr81 of 
p53, we took advantage of a protein structure prediction algorithm, I-TASSER (Iterative 
Threading ASSEmbly Refinement) [131-133]. Using I-TASSER, we generated predicted 
protein structure models for wild-type p53, R248W mutant p53 (a common DNA binding 
domain mutant), and a Thr81 phosphomimic p53 (T81E) (Figure 7). Analysis of wild-
type and mutant p53 showed distinct structural differences in the amino and carboxy 
termini. The Thr81 phosphomimic mutation (T81E) substantially changed the structure of 
the tetramerization/regulatory (TET/REG) domain compared to that of the 
unphosphorylated wild-type p53. The TET/REG domain of the T81E model more closely 
resembled the R248W mutant p53 model than the wild-type p53 model. The R248W 
mutation of p53 is one of the mutants that binds to p73 [135]. It is probable that it is this 
structural change in the TET/REG domain that enables p53 to interact with p73, which 
explains the original finding that wild-type p53 was unable to bind to p73. The results of 
our structural analysis implies that phosphorylation at Thr81 of p53 is permissive of 
binding to p73. We also produced in silico structural models of the S46D phosphomimic 
p53 and a R248W/T81E mutant p53 phosphomimic (Figure 7) to examine if there were 
any structural changes in these constructs. The TAD2 of the S46D phosphomimic was 
structurally similar to the T81E phosphomimic but distinct from either of the R248W 
mutant p53 models. Given that phosphorylation at Ser46 of p53 is needed for a robust 
apoptotic response, and phosphorylation at Thr81 of p53 causes a structural change 
similar to that of phosphorylation at Ser46, these data suggest that TAD2 and PRD are 
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integrated into important structural changes that are associated with induction of 
apoptotic genes.  Compared to mutant p53 alone (R248W), the Thr81 phosphomimic of 
R248W mutant p53 (R248W/T81E) causes an additional structural change in almost 
every single functional domain. This suggests that the use of a JNK inhibitor may reduce 
the binding of mutant p53 to p73 without completely ablating the interaction.  
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Figure 7. Predicted structure for a Thr81 phosphomimic reveals a possible mode of binding to p73. 
Structures (A) and amino acid coverage (B) of domains in wild-type and mutant p53. Whole protein 
represents amino acids 1-393 of p53. Transactivation domains 1 and 2 (TAD1/TAD2) represent amino 
acids 1-40 and 43-54. The proline rich domain (PRD) represents amino acids 63-97. The tetramerization 
and regulatory domains (TET/REG) represent amino acids 323-393. T81, Thr81; E, glutamic acid in T81E 
phosphomimic mutant domain. Arrows represent the region of a conformational change permissive of 
binding. From [1]. Reprinted with permission from AAAS.  
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3.4 Phosphorylation of Thr81 of p53 promotes a p53-p73 complex 
 Our structural data (Figure 7) combined with previous reports that mutant p53 
binds wild-type p73 and the observation of high basal activated JNK and Thr81 
phosphorylation of mutant p53 (Figure 4) led us to examine whether blocking JNK with 
the selective broad-spectrum, small-molecule inhibitor SP600125 could alter the mutant 
p53-p73 interaction endogenously. Mutant p53 was immunoprecipitated from lysates 
from TMD231 cells treated with DMSO or SP600125 and blotted for coincident 
pulldown of p73.  We found that p73 co-purified with mutant p53 and that binding 
decreased by 40% when JNK activity was blocked with SP600125 (Figure 8A). This data 
suggests that JNK has only a modest effect on the interaction between mutant p53 and 
p73, which was predicted in the structural data (Figure 7). We next tested whether wild-
type p53 and p73 were affected by phosphorylation of p53 by JNK. We transiently 
transfected H1299 cells with wild-type p53 and HA-tagged p73, then treated the 
transfected cells with DMSO or anisomycin.  Immunoprecipitation of wild-type p53 from 
cellular extracts shows that p73 co-purified only when JNK was activated with 
anisomycin (Figure 8B). To provide evidence that phosphorylation of Thr81 was 
necessary for wild-type p53 to co-purify with p73, we transiently transfected H1299 cells 
with wild-type p53 or the T81E phosphomimic. Immunoprecipitation of exogenous p53 
revealed that T81E, but not wild-type p53, co-purified with endogenous p73 (Figure 9A) 
Likewise, immunoprecipitation of endogenous p73 from extracts from U87 cells treated 
with DMSO, anisomycin, SP600125, or pretreated with SP600125 before anisomycin 
showed that endogenous wild-type p53 co-purified with p73 only when Thr81 was 
phosphorylated (Figure 8C).  These data substantially suggest that Thr81 phosphorylation 
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in p53 is critical for the formation of a wild-type p53-p73 complex. To definitively show 
that phosphorylation was crucial for the interaction, we used various p53 phosphomimics 
(T81E, S46D, T81E-S46D) and p73 produced in bacteria and performed Far-Western 
analysis to examine the requirement of Thr81 phosphorylation. We fixed recombinant 
wild-type p53, the phosphomimics, and two positive controls (MDM2 and MDMX) to 
nitrocellulose, then incubated the membrane with purified p73 and blotted for p73. In 
support of our cellular data presented above, the in vitro approach confirmed that p73 
bound only to T81E and not wild-type p53 or S46D p53 (Figure 9B). We also probed for 
p53 in a separate lane to show the relative amounts of p53 loaded per well (Figure 9B).  
Through overexpression, endogenous and recombinant approaches, we conclude that p73 
only binds to wild-type p53 that is phosphorylated at Thr81.   
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Figure 8. p53-p73 complex formation and activity. (A) Immunoprecipitation of p53 or control IgG from 
TMD231 cells treated with DMSO or SP600125 and western blotted for p73 and p53. Blots are 
representative of four independent experiments. (B) Data from Lindsey Mayo. Transient transfection of 
H1299 cells with p53, HA-p73 and treated with either DMSO or Anisomycin. Western blot of p53 and HA 
from p53 immunoprecipitated from cellular extracts. Blots are representative of two independent 
experiments. (C) Data from Lindsey Mayo. Immunoprecipitation of endogenous p73 from U87 cells treated 
with SP600125, anisomycin or both and western blot of phospho-Thr81, p53, and p73. Blots are 
representative of two independent experiments. From [1]. Reprinted with permission from AAAS. 
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Figure 9. The effect of T81E on p53-p73 complex formation. (A)  Data from Lindsey Mayo. 
Immunoprecipitation of p53 or control IgG and western blot of p53 and p73 from H1299 cells transfected 
with wild type p53 or T81Ep53. WCL is whole cell lysate from H1299 cells. Blots are representative of 
two independent experiments. (B) Data from Kristen Bredhold and Amber Kline. Far-Western analysis of 
p73 binding to p53.  Lane 1 corresponds to p53 and the phosphomimics of p53, and lane 2 is Mdm2 and 
MdmX. Blotting for p73 is detects binding to p53 and Mdm2 and MdmX (right panel).  The relative 
amount of p53 on the membrane is the left panel. Blots are representative of two independent experiments. 
From [1]. Reprinted with permission from AAAS. 
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To gain insight into where p53 and p73 interact, confocal immunofluorescence 
microscopy analysis was performed on MDA157, HME, or TMD231 cells grown on 
coverslips and treated with anisomycin, SP600125, or DMSO. Anisomycin treatment 
caused a significant increase of 38% in colocalization between p53 and p73 in the 
nucleus of p53–wild-type HME cells but not p53-mutant MDA157 cells (Figures 10 and 
11, Table 6).  Blocking JNK activity with SP600125 in TMD231 cells, which have 
mutant p53 and high basal activation of JNK, caused a significant decrease in the 
colocalization of mutant p53 and p73 in the nucleus (Figure 12 and Table 6), which is in 
accordance with the decrease in binding of mutant p53 and p73 (Figure 8A). To ensure 
that anisomycin was indeed activating JNK and increasing phosphorylation at Thr81, and 
that SP600125 was inhibiting JNK and decreasing phosphorylation at Thr81 of p53, the 
same cells were treated as described in the confocal experiments and lysates were 
Western blotted for active JNK and phosphorylated Thr81 p53 (Figure 13). 
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Figure 10. p53 activation and colocalization with p73 in MDA-MB-157 cells. Immunofluorescence of p53-
p73 colocalization in MDA157 cells treated with anisomycin or DMSO. Error bars represent standard error 
of the mean. Significance was determined using a two-tailed unpaired t test. Data is representative of three 
independent experiments. From [1]. Reprinted with permission from AAAS.  
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Figure 11. p53 activation and colocalization with p73 in HME1 cells. Immunofluorescence of p53-p73 
colocalization in HME cells treated with anisomycin or DMSO. Error bars represent standard error of the 
mean. Significance was determined using a two-tailed unpaired t test. Data is representative of three 
independent experiments. From [1]. Reprinted with permission from AAAS.  
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Figure 12. p53 activation and colocalization with p73 in TMD231 cells. Immunofluorescence of p53-p73 
colocalization in TMD231 cells treated with SP600125 or DMSO. Error bars represent standard error of the 
mean. Significance was determined using a two-tailed unpaired t test. Data is representative of three 
independent experiments. From [1]. Reprinted with permission from AAAS. 
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 A = p73, B = p53 Manders’ A Standard Error Manders’ B Standard Error 
MDA157 
DMSO (n = 109) 0.468 0.021 0.389 0.021 
Anisomycin (n = 61) 0.458 0.023 0.448 0.018 
Significance (p value) 0.763   0.060   
TMD231 
DMSO (n = 53) 0.353 0.020 0.404 0.018 
SP600125 (n= 49) 0.114 0.012 0.398 0.009 
Significance (p value) 7.84E-17   0.765   
HME 
DMSO (n = 72) 0.519 0.006 0.281 0.017 
Anisomycin (n = 67) 0.560 0.011 0.371 0.024 
Significance (p value) 0.001   0.002   
Table 7. Manders’ Coefficients for microscopy colocalization analysis. Mander’s A and B coefficients were 
generated using p73 as channel A and p53 as channel B within the Imaris software. Significance was 
determined using a two-tailed unpaired t test. From [1]. Reprinted with permission from AAAS. 
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Figure 13. JNK activation or inhibition in HME, MDA157, and TMD231 cell lines. Western blotting for 
activated JNK (p-JNK) and phosphorylated p53 (at Thr81; p-p53) in whole-cell lysates from HME and 
MDA157 cells treated with 30 µM anisomycin or DMSO for 6 hours and TMD231 cells treated with 25 
µM SP600125 or DMSO for 6 hours. From [1]. Reprinted with permission from AAAS.  
  
55 
3.5 The JNK-initiated p53-p73 pathway is important for apoptosis 
 Phosphorylation of Thr81 of p53 resulted in its interaction with p73 (Figures 8 
and 9) and an increased abundance of PUMA (Figure 5B).  Therefore, the necessity of 
p53, p73, and JNK activation for the induction of apoptosis was examined. The removal 
of p53 in p53–wild-type BJ cells resulted in resistance to JNK-activated cell death by 
anisomycin treatment (Figure 14A). Specifically, treatment with anisomycin for 9 hours 
initiated a steady increase in the abundance of BAX and PUMA, which was prevented by 
shRNA knockdown of p53. In contrast, the abundance of BAX increased after 6 hours of 
anisomycin treatment; this may be due to the cells overcoming the shRNA knockdown at 
6 hours in response to prolonged anisomycin-induced stress (Figure 14A).   
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Figure 14. Downstream effects of the p53-p73 pathway. (A) Data from Ciaran McAtarsney. Western blot 
of Bax, PUMA, p53 and actin in cellular extracts from empty vector control (E.V) and p53-knockdown 
(shp53) BJ cells treated with anisomycin for the indicated time. Both E.V. and shp53 lanes where 
developed from the same western blot. Blots are representative of three independent experiments. (B) Data 
from Ciaran McAtarsney. Cell viability assay of E.V. and shp53 BJ cells stained with Methylene Blue. 
Cells were treated with DMSO or anisomycin for 9 hours. Data is representative of three independent 
experiments. From [1]. Reprinted with permission from AAAS.  
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Figure 15. Effects of the p53-p73 pathway on survival. (A) Data from Ciaran McAtarsney. Relative GFP 
fluorescence was measured in GFP shp53 and LVTHM empty vector BJ cells. Cells were treated with 
DMSO or anisomycin for 48 hours. Relative fluorescence was derived from DMSO controls. Data is 
representative of four independent experiments. Significance was determined by a two-tailed unpaired t test 
(***, P<0.005) (B) GFP fluorescence was measured in H1299 cells transfected with GFP alone or GFP and 
either wild-type or T81A p53, then treated with DMSO or anisomycin. Fold change survival was calculated 
as the change in survival from DMSO to anisomycin treatment and normalized to the GFP alone control. 
Error bars represent standard error of the mean. Data is representative of three independent experiments. 
From [1]. Reprinted with permission from AAAS.  
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The apoptotic resistance conferred to BJ cells transfected with p53-shRNA was 
further investigated using a methylene-blue cell death assay (Figure 14B) and by 
assessing cell number as a factor of green fluorescent protein (GFP) (shRNA vector) 
signal (Figure 15A). Loss of p53 improved cell viability through anisomycin treatment 
(Figures 14B and 15A), suggesting that the lack of the p53-p73 complex results in 
resistance to apoptosis. To test the impact of specifically Thr81 phosphorylation on cell 
death, GFP and either wild-type p53 or a p53 mutant that cannot be phosphorylated at 
T81 (T81A) were expressed in H1299 cells and survival was examined by GFP 
fluorescence after anisomycin treatment. The data revealed an increase in survival of 
175% in cells expressing T81A point mutation compared to wild-type p53 (Figure 15B), 
confirming previously published observations with the T81A mutant [151] and that 
Thr81 phosphorylation in p53 is critical to cell stress-induced apoptosis.  
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Figure 16. Cell fate is dictated by p53/p73 complex formation. Apoptotic stimuli, for example DNA 
damage, results in the phosphorylation and activation of JNK. JNK phosphorylates wild-type p53 (green 
hexagons) at Thr81 causing a structural change in p53 and the subsequent binding of p73 (red diamonds). 
This complex drives the transcription of PUMA and BAX leading to apoptosis. Mutant p53 (blue 
hexagons) does not require phosphorylation by JNK to form a complex with p73. Phosphorylation of 
mutant p53 instead serves to improve the ability of p53 to bind with p73, hence increasing total complex 
formation. However, PUMA and BAX are not transcribed due to mutant p53’s dysfunctional DNA binding 
domain as well as the sequestering of p73 by complex formation. This decreases the apoptotic signal and 
promotes tumor survival. Schematic made by Ciaran McAtarsney. From [1]. Reprinted with permission 
from AAAS.  
60 
3.6 Discussion 
 The tumor suppressor p53 is highly studied given its role in regulating many 
cellular activities and responses, including cell cycle arrest, DNA repair, cell death, and 
metabolism. Its family member p73 has some described overlapping functions; yet, 
unlike p53, p73 is rarely mutated in human cancer. While p73 is rarely mutated, mutation 
of p53 may function as a dominant negative to ablate p73 activity [135]. The regulation 
of p53 is extremely important given that its differential regulation can dictate distinct 
binding partners and, consequently, distinct outcomes through transcriptional targets, 
such as PTEN to promote apoptosis versus Mdm2 to promote re-entry into the cell cycle 
and survival [36, 155]. Increased abundance of PTEN, a protein/lipid phosphatase that 
inhibits the PI3K (phosphatidylinositol 3-kinase)–AKT (protein kinase B) pathway, can 
protect p53 from Mdm2-mediated degradation induced by AKT [30, 129, 147, 156, 157]. 
Thus, p53 can selectively induce PTEN expression and programmed cell death instead of 
the autoregulatory feedback loop with Mdm2 to promote cell survival [37, 147]. 
Moreover, PTEN can form a complex with p73 and bind to the PUMA promoter to 
increase its expression, leading to the induction of apoptosis [130]. These molecular and 
biochemical studies are supported by genetic studies in mice where the loss of p53, p73, 
or PTEN confers resistance to apoptotic stimuli and an increase in neoplastic 
development [3, 137, 158-160].  Thus, an effective response to apoptotic stimuli requires 
the integration of numerous intact tumor suppressors, yet how these tumor suppressors 
are signaled to form a complex has not previously been clearly defined.  
There are well-characterized kinase signaling pathways that phosphorylate p53 
and p73 in response to DNA damage, but some phosphorylation sites appear to be 
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dispensable for the induction of apoptosis. It has been reported by several groups that 
Ser46 and Thr81 are important for the induction of apoptosis [144, 145, 147, 149]. 
Homeodomain-interacting protein kinase 2 (HIPK2) and the mitogen-activated protein 
kinase p38 reportedly phosphorylate Ser46 of p53, whereas JNK, which plays dual roles 
in cellular proliferation and cell death [161], phosphorylates Thr81 of p53 [144, 145, 147, 
149]. One of JNK’s substrates is p73, which mediates JNK-induced apoptosis [162], but 
it was unclear how. Analysis of apoptosis by the JNK-p73 axis in that previous study 
[162] was performed in cells that maintained expression of wild-type p53, and notably, 
p53 abundance does not directly correlate with its activity; for example, neddylation of 
p53 in response to growth factor signaling renders p53 stable but inactive [47]. 
Untransformed cell lines have an intact apoptotic pathway and deneddylating enzymes, 
tumor suppressors, active kinases, and post-translational modification enzymes that are 
activated in response to genotoxic stress that provide a robust induction of apoptosis.     
There is renewed interest in p53 family member interactions, and several studies have 
highlighted the importance of the interactions between different family members [163-
165]. Our studies have linked the JNK-p53-p73 proteins showing that phosphorylation of 
p53 at Thr81 by JNK is permissive of a p53-p73 interaction. Notably, our structural 
modeling analysis revealed that the structure of phosphorylated Thr81 is nearly identical 
to that of R248W. Therefore, activated JNK can convert wild-type p53 to mimic mutant 
p53 with regards to binding to p73 by exposing the DNA binding domain.  Ser46 is 
proximal to the proline rich domain in the second transactivation domain, which may be 
important for additional structural changes to recruit other factors for gene expression.  
However, we also found that phosphorylation of Ser46 has no effect on binding to p73, 
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supporting that Ser46 phosphorylation may instead be required for recruiting additional 
coactivators.  The JNK-mediated interaction between wild-type p53 and p73 provides 
biochemical evidence in support of the existing animal models and gene dose sensitivity 
of p53 and p73 to apoptosis [3]. We also show that in mutant p53 cells, JNK activity is 
increased resulting in a mutant p53/wild-type p73 complex with mutant p53 acting as a 
dominant negative partner of p73. These data are consistent with previous reports 
showing that mutant p53/p73 form a complex [136]. The p53/p73 complex mediates 
apoptosis in cells that express wild-type p53, but survival in cells that express mutant 
p53. Thus, our findings refine our understanding of how cells promote, or in certain 
contexts circumvent, the p53 apoptotic signaling axis.  
 In addition to the apoptotic function of p53, the tumor suppressor also plays a 
major role in the inhibition of angiogenesis [80, 156, 166-172]. The mechanisms 
governing the activation of p53 for inhibition of angiogenesis have not been thoroughly 
explored. However, some of the known activators of p53 have been shown to play a role 
in angiogenesis inhibition independent of p53. For example, in addition to its regulation 
of HIFa subunits, the Von Hippel-Lindau (VHL) tumor suppressor protein is also able to 
bind to p53 in response to genotoxic stress, resulting in stabilization and transactivation 
of p53 [173]. Additionally, while p73 can synergize with p53 in response to JNK 
activation, it is also able to destabilize HIF1a in response to hypoxia [174]. While there 
has been no direct link between these activators of p53 and the ability of p53 to inhibit 
angiogenesis, these pathways were investigated to determine if there was any mechanism 
that could activate the anti-angiogenesis activity of p53.  
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4. Mdm2 functions as an angiogenic switch through its regulation of VHL 
4.1 Introduction 
The murine double minute 2 (Mdm2) oncoprotein is detectable in 40-90% of 
human cancers and is correlated with high-grade metastatic tumors and poor patient 
outcome [175]. The current paradigm is that the function of Mdm2 is to regulate the 
tumor suppressor p53[19, 20]. p53 plays a major role in the DNA damage response and 
cell cycle arrest by activating transcription of CDKN1A, BAX, BBC3 and others [176-
178]. p53 can also regulate transcription of genes involved in metabolism, angiogenesis, 
stemness, migration, and invasion [reviewed in [6]]. In recent years it has come to light 
that some of the noncanonical p53 targets may be more important for tumor suppression 
by p53. For instance, p53 mutated at three key lysines that are needed for p53 mediated 
cell cycle arrest, apoptosis, and senescence is still capable of tumor suppression [179]. 
Additionally, a mouse model that is deficient in p53-dependent apoptosis is not prone to 
cancer development [180]. One area of tumor suppression by p53 that is not well 
understood is its regulation of angiogenesis. p53 is able to activate transcription of 
several inhibitors of angiogenesis such as THSB1, SERPINE1, and COL18A1 and 
suppress transcription of the proangiogenic VEGF, thereby tilting the balance of 
angiogenesis [166, 168, 170, 172, 181].  
Mdm2 can play a role in angiogenesis through several mechanisms. In response to 
hypoxia, Mdm2 binds directly to hypoxia inducible factor 1a (HIF1a) resulting in 
increased VEGF expression [96-100]. Additionally, Mdm2 can bind to and stabilize the 
3’ UTR of VEGF mRNA [76]. Our lab recently showed that Mdm2 can be converted to a 
nedd8 E3 ligase in response to phosphorylation by c-Src. Mdm2 can then neddylate p53, 
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rendering it stable but inactive [47]. Another mechanism of p53 stabilization involves the 
von Hippel-Lindau tumor suppressor protein (VHL), which binds to p53 and blocks 
Mdm2-mediated degradation of p53 [173]. VHL is frequently mutated in sporadic clear 
cell renal cell carcinomas and it plays an important role in hypoxic signaling through its 
regulation of HIFa subunits [108, 122]. Interestingly, p53 is rarely mutated in renal cell 
carcinomas, but p53 pathway genes are commonly downregulated suggesting a different 
mechanism of p53 pathway inhibition [182]. In response to DNA damage, VHL can bind 
p53 and recruit p300 to acetylate specific lysines of p53, in turn blocking potential 
ubiquitination sites and activating p53 transcriptional activity of CDKN1A and BAX 
[173]. Interestingly, the region of VHL that binds to p53 contains a lysine that has been 
shown to be neddylated by an unknown E3 ligase [126, 183]. Previously, the neddylation 
of VHL was shown to be important for the formation of the fibronectin extracellular 
matrix, but its effect on binding to p53 was not examined. 
Because VHL is able to stabilize and activate p53, and Mdm2 can disrupt p53 
activity, the impact of Mdm2 on VHL stabilization and activation of p53 was examined. 
We hypothesize that the VHL-p53 interaction results in an increase in production of 
inhibitors of angiogenesis and that Mdm2 may disrupt the binding of VHL to p53 through 
conjugation of nedd8. To this end, we have examined the effect of VHL on p53 
antiangiogenic target genes as well as the ability of Mdm2 to disrupt the VHL/p53 
pathway. Our study provides an explanation for the changes in p53 pathway genes seen 
in renal cell carcinomas as well as a reason for p53 tumor suppression in the absence of 
apoptosis, senescence, or cell cycle arrest. 
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4.2 p53 target genes for apoptosis and angiogenesis are altered by VHL status 
The tumor suppressor p53 is able to inhibit cancer progression via several 
different mechanisms, including the transcription of pro-apoptotic factors and anti-
angiogenic factors [166, 170-172, 181]. Activation of p53 is a highly regulated process 
involving many other tumor suppressor proteins [1, 184]. It has been previously reported 
that VHL can bind to p53 and increase the transcription of the pro-apoptotic BAX and 
CDKN1A [173]. Using a subset of patient data for renal cell carcinomas, we determined 
the effects of mutations in the domain of VHL that binds to p53 on the mRNA levels of 
these target genes, as well as several other genes that p53 regulates. Mutations in the a 
domain of VHL caused an increase in mRNA for BAX, CDKN1A, and BBC3 (Figure 
17A). Likewise, the mRNA levels of the antiangiogenic factors THBS1, COL18A1, and 
SERPINE1 were also increased when the a domain of VHL was mutated (Figure 17B). 
The change in mRNA expression suggests that there is some modification to the a 
domain of VHL that may block its interaction with p53. THBS1 codes for the protein 
thrombospondin-1 (TSP-1), a potent inhibitor of angiogenesis that is known to be 
regulated by p53 [166]. To confirm the importance of VHL on the transcription of 
THBS1, we analyzed the luciferase activity of a TSP-1 reporter in the 786-O and RCC4 
cell lines with or without VHL transduction. In both cell lines, transduction with VHL 
increased the reporter activity by 3-4 fold (Figure 18A). In order to determine if the 
increase in THBS1 transcription resulted in an increase in secreted TSP-1 protein, we 
analyzed conditioned media from 786-O and RCC4 cells for TSP-1 levels. Similar to the 
reporter activity results, VHL transduction increased the secreted TSP-1 protein levels by 
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~2 fold (Figure 18B). We also analyzed conditioned media using an angiogenesis 
microarray and saw consistent results (Figure 19).   
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Figure 17. p53 target genes for apoptosis and angiogenesis are altered by VHL status. A) Log counts per 
million for BAX, CDKN1A, and BBC3. Only samples with wild-type p53 were included in the analysis. 
WT refers to wild-type VHL status, and a mutant refers to any point mutation within the a domain of 
VHL. Error bars represent SEM. P values were calculated using an unpaired t test. (B) Log counts per 
million THBS1, COL18A1, and SERPINE1. Only samples with wild-type p53 were included in the 
analysis. WT refers to wild-type VHL status, and a mutant refers to any point mutation within the a 
domain of VHL. Error bars represent SEM. P values were calculated using an unpaired t test. (C) Log 
counts per million VHL and TP53. Only samples with wild-type p53 were included in the analysis. WT 
refers to wild-type VHL status, and a mutant refers to any point mutation within the a domain of VHL. 
Error bars represent SEM. P values were calculated using an unpaired t test. 
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Figure 18. VHL increases transcription of THBS1 and secretion of TSP-1. (A) Luciferase assay in 786-O 
and RCC4 cells with or without VHL for thrombospondin-1 plotted as relative luciferase units. Means are 
calculated from three biological replicates. Error bars represent SEM. Statistics were calculated using an 
unpaired t test (***p<0.001). (B) Dot blot assay to measure protein level of thrombospondin-1 in media 
secreted from 786-O or RCC4 cells with or without VHL. Means are calculated from three biological 
replicates. Error bars represent SEM. Statistics were calculated using an unpaired t test (***p<0.001).  
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Figure 19. Angiogenesis array with conditioned media from 786-O cells under hypoxia 
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4.3 Mdm2 binds to VHL and inhibits VHL-p53 complex formation under hypoxia 
In order to determine what mechanisms may inhibit VHL-p53 complex formation, we 
expressed exogenous Mdm2, VHL, and p53 in H1299 cells with or without hypoxia and 
analyzed complex formation by immunoprecipitation. VHL forms a complex with p53 
under both normoxia and hypoxia, but that Mdm2 inhibits VHL/p53 complex formation 
under hypoxia (Figure 20A). We next analyzed complex formation between VHL and 
Mdm2 in H1299 cells and saw that VHL and Mdm2 form a complex under both 
normoxia and hypoxia (Figure 20B). Since Mdm2 bound to VHL under both normoxia 
and hypoxia, but only inhibits VHL-p53 complex formation under hypoxia, we 
hypothesized that Mdm2 might be causing a posttranslational modification to VHL under 
hypoxia. Src phosphorylation of Y281 and Y302 of Mdm2 causes Mdm2 to become a 
neddylating ligase, and Src becomes phosphorylated at Y416 in response to hypoxia [47, 
185]. We verified Src activation in our system by analyzing phosphorylation of Y416 in 
response to hypoxia in the RCC4 cell line and found that Src does become more active 
after exposure to hypoxia (Figure 20C). Of note, there is a neddylation site at lysine 159 
of VHL that overlaps with the region that is required for binding to p53 (Figure 21) [126, 
183]. Mdm2 is able to function as a nedd8 E3 ligase under growth conditions [47], so we 
rationalized that Mdm2 could be neddylating VHL under hypoxia if the right growth 
conditions are present. To further confirm the effect of Mdm2 on VHL-p53 complex 
formation, VHL or VHL and Mdm2 were transiently expressed in 786-O cells and 
stained the cells with VHL and p53 antibody for immunofluorescence. Supporting the 
immunoprecipitation data, VHL colocalized with p53 under normoxia and Mdm2 
inhibited p53/VHL colocalization under hypoxia (Figure 22A and 22B). 
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Figure 20. Mdm2 binds to VHL and inhibits VHL-p53 complex formation under hypoxia. (A) Transient 
transfection in H1299 cells followed by incubation in either normoxia or hypoxia. p53 was 
immunoprecipitated from cell lysates and subjected to analysis by Western blot. (B) Transient transfection 
in H1299 cells followed by incubation in either normoxia or hypoxia. VHL was immunoprecipitated from 
cell lysates and subjected to analysis by Western blot. (C) Hypoxia timecourse in RCC4 cells followed by 
Western blot. 
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Figure 21. Schematic of VHL protein showing the primary site of neddylation, as well as the region that 
has been shown to be indispensable for binding to p53. 
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Figure 22. Mdm2 inhibits VHL-p53 complex formation under hypoxia. (A) Transfection of 786-O cells 
with VHL or VHL and Mdm2 under normoxia. Cells were fixed and stained with p53 or VHL and 
subjected to immunofluorescence confocal microscopy. Scale bar is 25 µm. (B) Transfection of 786-O cells 
with VHL or VHL and Mdm2 under hypoxia. Cells were fixed and stained with p53 or VHL and subjected 
to immunofluorescence confocal microscopy. Scale bar is 25 µm. 
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4.4 Neddylation of VHL by Mdm2 interferes with VHL-p53 complex formation 
To examine the importance K159 neddylation on VHL-p53 complex formation, a 
K159E point mutant of VHL was utilized. The K159E mutant was isolated from a patient 
with Type 2C VHL disease, which only develops pheochromocytoma [120, 126]. H1299 
cells were transiently transfected with p53 and either WT VHL or K159E VHL under 
normoxia or hypoxia and analyzed VHL-p53 complex formation by immunoprecipitation 
(Figure 23A). VHL-p53 complex formation increased with the K159E mutant compared 
to WT, but this increase was very dramatic under hypoxia which supports VHL becoming 
neddylated under hypoxia. Treatment with MLN4924, a global neddylation inhibitor, 
resulted in increased VHL-p53 complex formation in 786-O (Figure 23B) and MCF7 
(Figure 23C) cells. To determine if Mdm2 is the nedd8 E3 ligase for VHL, we first 
examined if Mdm2 binds directly to VHL, and if so what domain of VHL binds to Mdm2 
using recombinant proteins produced and purified from E. Coli. The a domain of VHL 
interacts directly with Mdm2 (Figure 24A). Purified recombinant proteins were then used 
in a cell free assay to determine if Mdm2 was able to neddylate VHL. Using GST-VHL, 
His-Mdm2, His-Src, and neddylation reaction components, we saw that Mdm2 
neddylates VHL. In support of previously published data on the activation of Mdm2 [47], 
the neddylation of VHL is increased with the addition of Src (Figure 24B). To determine 
if VHL is neddylated by Mdm2 in a tumor cell model, Mdm2 was transiently expressed 
in 786-O cells that were transduced with WT VHL or a control vector. 
Immunoprecipitation of nedd8 showed complex formation with VHL when Mdm2 was 
expressed, and this interaction increased under hypoxia (Figure 24C). Neddylation of 
VHL was further investigated by transiently expressing components of our system with 
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His-nedd8 and performed a Ni-NTA pulldown under denaturing conditions. Neddylation 
of WT VHL was much higher than K159E, CA-Src increased the abundance of the 
neddylated form of VHL, and MLN4924 reduced the abundance of the neddylated form 
of VHL (Figure 24D).  
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Figure 23. Neddylation impacts p53-VHL complex formation. (A) Transient transfection in H1299 cells 
under normoxia or hypoxia. Cell lysates were immunoprecipitated for HA and subjected to analysis by 
Western blot. (B)Immunoprecipitation of VHL from 786-O cells treated with the neddylation inhibitor 
MLN4924 and Western blotted for p53 and VHL. (C) Data from Lindsey Mayo. Immunoprecipitation of 
p53 or IgG control from MCF7 cells treated with MLN4924 for various indicated times and Western 
blotted for VHL and p53. 
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Figure 24. Mdm2 binds directly to the alpha domain of VHL and neddylates VHL at K159. (A) Data from 
Lindsey Mayo. His-pulldown for Mdm2 using GST, GST-alpha VHL, GST-beta VHL, or GST-VHL and 
Western blotted for GST and Mdm2. (B) Cell free neddylation assay using recombinant proteins. Reactions 
were separated by SDS-PAGE and analyzed by Western blot. (C) Immunoprecipitation of endogenous 
nedd8 from 786-O cells transfected with Mdm2 and subjected to hypoxia and Western blotted for VHL and 
Mdm2. (D) Ni-NTA pulldown for His-nedd8 in H1299 cells in a transient transfection and subjected to 
treatment with MLN4924. Samples were separated with SDS-PAGE and analyzed by Western blot for 
VHL and Mdm2. 
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Figure 25. Neddylation of VHL by Mdm2 reduces VHL-p53 complex formation. (A) Data from Lindsey 
Mayo. Immunoprecipitation of p53 or IgG control from MCF7 cells treated with PP1 or a control and 
Western blotted for nedd8, p53, and VHL. (B) Cell free neddylation assay using recombinant proteins. 
Reactions were separated by SDS-PAGE and analyzed by Western blot. (C) Data from Lindsey Mayo. 
Immunoprecipitation of VHL, Mdm2, or IgG control from BJ or MCF7 cell extracts and Western blotted 
for Mdm2, VHL, and nedd8. 
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4.5 VHL colocalizes with p53 under hypoxia or with treatment of MLN4924 
Immunofluorescence confocal microscopy was used to examine the intracellular 
co-localization of VHL-p53 complex. 786-O cells were transiently transfected with WT 
VHL, K159E VHL, and Mdm2 and stained with antibody against VHL and p53. Under 
normal oxygen, WT VHL colocalized with p53 when Mdm2 was not transfected or when 
Mdm2 was transfected with the addition of the neddylation inhibitor MLN4924 (Figure 
26A). The K159E point mutant of VHL colocalized with p53 under all conditions tested 
in normal oxygen, including when Mdm2 was transfected (Figure 27A). Under hypoxic 
conditions, WT VHL only colocalized with p53 when cells were treated with MLN4924 
(Figure 26B). There was a slight decrease in colocalization of WT VHL and p53 when 
Mdm2 was co-transfected, but it is likely that endogenous Mdm2 is also inhibiting the 
interaction between VHL and p53 under hypoxia. There was an increase in colocalization 
of K159E VHL and p53 under hypoxia as compared to normoxia (Figure 27B). 
Transfection of Mdm2 with K159E VHL under hypoxia did not interfere with VHL-p53 
complex formation. Interestingly, treatment with MLN4924 caused an additional increase 
in K159E VHL-p53 complex formation under hypoxia, suggesting that there may be 
additional neddylation sites that are important for the interaction of VHL with p53. To 
test colocalization in an endogenous system, Caki-1 cells were treated with MLN4924 or 
DMSO (Control) under normoxia or hypoxia and stained with antibodies against VHL 
and p53. Similar to the results seen with the 786-O cell line, p53 and VHL formed a 
complex under normoxia and that complex formation increased with MLN4924 treatment 
(Figure 28A). Under hypoxia, there was not as much of a loss of complex formation as 
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seen with 786-O cells, but this could be due to different protein levels of endogenous 
Mdm2 between cell lines (Figure 28B).  
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Figure 26. VHL colocalizes with p53 under hypoxia or with treatment of MLN4924. (A) Transfection of 
786-O cells with VHL or VHL and Mdm2 under normoxia. Cells were treated with MLN4924 or a control, 
fixed, and stained with p53 or VHL and subjected to immunofluorescence confocal microscopy. Scale bar 
is 25 µm. (B) Transfection of 786-O cells with K159E VHL or K159E VHL and Mdm2 under normoxia. 
Cells were treated with MLN4924 or a control, fixed, and stained with p53 or VHL and subjected to 
immunofluorescence confocal microscopy. Scale bar is 25 µm. 
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Figure 27. K159E VHL colocalizes with p53 under hypoxia, but also with treatment of MLN4924. (A) 
Transfection of 786-O cells with VHL or VHL and Mdm2 under hypoxia. Cells were treated with 
MLN4924 or a control, fixed, and stained with p53 or VHL and subjected to immunofluorescence confocal 
microscopy. Scale bar is 25 µm. (B) Transfection of 786-O cells with K159E VHL or K159E VHL and 
Mdm2 under hypoxia. Cells were treated with MLN4924 or a control, fixed, and stained with p53 or VHL 
and subjected to immunofluorescence confocal microscopy. Scale bar is 25 µm. 
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Figure 28. VHL colocalizes with p53 under hypoxia or with treatment of MLN4924. (A) 
Immunofluorescence microscopy of Caki-1 cells treated with MLN4924 or a control under normoxia. Cells 
were fixed and stained with VHL and p53. Scale bar is 50 µm. (B) Immunofluorescence microscopy of 
Caki-1 cells treated with MLN4924 or a control under hypoxia. Cells were fixed and stained with VHL and 
p53. Scale bar is 50 µm. 
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4.6 VHL increases the acetylation of p53 under hypoxia, leading to increased 
transcription and secretion of TSP-1 
There are many signals that can activate p53-dependent transcription, but acetylation is 
necessary in order to change the structure of p53 to expose the DNA binding domain to 
bind to DNA [reviewed in [186]]. It has previously been shown that VHL activation of 
p53 results in acetylation at K373/382 of p53 in response to DNA damage [173]. Because 
the pathway we are focused on is impacted by hypoxia, the role of VHL on acetylation of 
p53 in response to hypoxia was examined. We found that VHL is required for the 
acetylation of p53 at K373/382 in response to hypoxia (Figure 29A). To determine if the 
activation of p53 would lead to increased transcription of THBS1, the luciferase activity 
of a THBS1 reporter gene in response to hypoxia with or without VHL was examined. 
VHL reconstitution resulted in a significant increase in THBS1 transcription, but this 
increase was negated by hypoxia (Figure 29B).  Interestingly, treatment with MLN4924 
overcame the hypoxia-dependent decrease in THBS1 transcription (Figure 29B). To 
verify that the changes in THBS1 transcription correlate with a change in secretion, we 
analyzed the protein levels of secreted TSP-1 by ELISA. As expected, VHL 
reconstitution increased the secretion of TSP-1 in Caki-1, 786-O, and RCC4 cells (Figure 
30). Under hypoxia, TSP-1 secretion was almost identical in control or VHL positive 
cells. With knockdown p53, however, there was a marked decrease in TSP-1 secretion 
under hypoxia as compared with control cells with knockdown p53 (Figure 30). These 
data support our hypothesis that p53 and VHL are both required for a robust induction of 
TSP-1 in response to hypoxia.   
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Figure 29. VHL increases the acetylation of p53 under hypoxia, leading to increased transcription of TSP-
1. (A) Transient transfection of H1299 cells with p53 or p53 and VHL. Cells were subjected to hypoxia and 
lysed for analysis by SDS-PAGE and Western blotted for HIF1, Ac-p53 K373/382, p53, and GAPDH. (B) 
Luciferase assay for thrombospondin-1 in 786-O cells treated with MLN4924 and subjected to hypoxia. 
Means are plotted as relative luciferase units and calculated from three biological replicates. Error bars 
represent SEM. Statistics were calculated using an unpaired t test. 
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Figure 30. VHL increases the secretion of TSP-1 through p53 transactivation. (A) Enzyme-linked 
immunosorbent assay for TSP-1 using a 10% dilution of conditioned media from Caki-1 cells under 
hypoxia and/or MLN4924 treatment. Means from three biological replicates are plotted. Error bars 
represent SEM. Statistics were calculated using an unpaired t test. (B and C) Enzyme-linked 
immunosorbent assay for TSP-1 using a 10% dilution of conditioned media from 786-O or RCC4 cells with 
knockdown p53 under hypoxia. Means from three biological replicates are plotted. Error bars represent 
SEM. Statistics were calculated using an unpaired t test (*p<0.05, **p<0.01, ***p<0.001). 
  
87 
4.7 p53 and TSP-1 inhibit Human Umbilical Vein Endothelial Cell network formation 
There are many factors that dictate whether or not angiogenesis will progress in a 
tumor. While it is evident that TSP-1 secretion is increased, we wanted to gain a more 
holistic view of how the p53/VHL pathway affects angiogenesis. To this end, H1299 
cells were transfected with p53 and either WT VHL or K159R VHL and harvested 
conditioned media. Human Umbilical Vein Endothelial Cells (HUVECs) were then 
cultured in the conditioned media on growth factor reduced matrigel to monitor network 
formation as a readout for angiogenic potential. The addition of K159R VHL resulted in 
a significant decrease in network branch points compared to p53 alone (Figure 31A and 
31B). Additionally, adding an antibody against TSP-1 to the conditioned media reversed 
this decrease resulting in a significant increase in network branch points. We next 
knocked down p53 in 786-O and RCC4 cells that had been previously transduced with 
VHL and harvested conditioned media under normoxia and hypoxia. Conditioned media 
from 786-O cells with knockdown p53 caused a statistically significant increase in 
network branch points compared to both normoxia and a vector control under normoxia 
or hypoxia (Figure 32A). Similar to results seen using conditioned media from H1299 
cells, the addition of an antibody to TSP-1 caused an increase in branch point formation. 
Conditioned media from RCC4 cells induced angiogenesis in a similar pattern, with the 
exception that hypoxia alone was sufficient to cause an increase in branch point 
formation in the control cells (Figure 32B). Of note, 786-O cells are naturally null for 
HIF1a, but maintain HIF2a. RCC4 cells maintain both HIF1a and HIF2a expression, 
which may explain the more robust response to hypoxia in that cell line. All of these data 
are summarized in the schematic in Figure 33. 
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Figure 31. p53 and TSP-1 inhibit Human Umbilical Vein Endothelial Cell network formation through 
VHL. (A) Network formation assay using conditioned media from transiently transfected H1299 cells. (B) 
Network branch points were quantified and plotted as the mean of three biological replicates. Error bars 
represent SEM. Statistics were calculated with an unpaired t test. 
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Figure 32. p53 and TSP-1 inhibit Human Umbilical Vein Endothelial Cell network formation. (A) Network 
formation assay using conditioned media from 786-O cells with VHL, VHL with knockdown p53, or VHL 
and an antibody against TSP-1 under normoxia or hypoxia. Network branch points were quantified and 
plotted as the mean of three biological replicates. Error bars represent SEM. Statistics were calculated with 
an unpaired t test (*p<0.05, **p<0.01, ***p<0.001). (B) Network formation assay using conditioned media 
from RCC4 cells with VHL, VHL with knockdown p53, or VHL and an antibody against TSP-1 under 
normoxia or hypoxia. Network branch points were quantified and plotted as the mean of three biological 
replicates. Error bars represent SEM. Statistics were calculated with an unpaired t test (*p<0.05, **p<0.01, 
***p<0.001). 
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Figure 33.  Schematic of the p53-VHL pathway being inhibited by Mdm2. Left: hypoxia results in VHL-
p53-p300 complex to acetylate p53 for induction of antiangiogenic genes. Right: Src phosphorylation of 
Mdm2 results in pVHL neddylation and prevents the p53-VHL complex.  
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4.8 Discussion 
In this study we describe how an antiangiogenic pathway involving p53 and VHL 
can be disrupted by the neddylating activity of Mdm2. These data highlight an evolving 
understanding of both VHL and Mdm2 in the control of angiogenesis. The role of VHL 
in regulating angiogenesis through HIFs has been well studied and the mechanisms 
governing that interaction are well understood [108-111, 128, 187]. The impact of Mdm2 
on angiogenesis has been previously described, but there is a gap in our understanding of 
the mechanisms Mdm2 uses to promote angiogenesis. Mdm2 is able regulate 
angiogenesis in many ways independent of HIF1a and VEGF stabilization [188-191]. It 
is probable that there are unknown functions of Mdm2 that can promote angiogenesis in 
the right signaling environment. 
 Recent work in our lab suggests that Mdm2 is a driving force for early stage 
metastasis, which implicates Mdm2 in the vascularization of a tumor as it moves from 
dormancy to malignancy [101]. In that study, we showed that Mdm2 is a driving force for 
epithelial to mesenchymal transition as well as early stage metastasis (Figure 34). We 
have also recently shown that Mdm2 is converted to a neddylating enzyme in response to 
phosphorylation by the kinase c-Src. In response to various growth conditions c-Src 
phosphorylates Mdm2, which in turn neddylates p53 to render it stable but inactive [47]. 
c-Src governs many tumorigenic pathways, including angiogenesis [192]. This led us to 
examine the effect of the c-Src/Mdm2 pathway on angiogenesis inhibition regulated by 
p53. Mdm2 has been shown to block the transcriptional activity of p53 independent of its 
ubiquitination and neddylation functions in an indirect manner, so we decided to 
investigate coactivators of p53 as potential targets of Mdm2.   
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Figure 34. Mdm2 promotes epithelial to mesenchymal transition. (A) MDA-MD-468 cells were transduced 
with shMdm2 and treated with a control (Mock) or TGFb in normoxia or hypoxia. Cells were lysed 48 
hours after treatment and lysates were separated with SDS-PAGE followed by Western blotting for Mdm2, 
vinculin, E-cadherin (epithelial marker), and several mesenchymal markers including SNAI1, vimentin, 
and N-cadherin. (B) Microscopy images of MDA-MB-468 cells with shMdm2 and treated with a control 
(Mock) or TGFb. Images were taken 48 hours after treatment and show that Mdm2 is required for a 
mesenchymal phenotype. Data published in [101] 
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 The canonical function of Mdm2 is its regulation of p53 via ubiquitination and 
subsequent degradation. In response to DNA damage, p53 activates transcription of 
Mdm2 which then ubiquitinates p53 in an autoregulatory feedback loop [19, 20]. In 
addition to its regulation of p53, Mdm2 has many other interactions that impact various 
coactivators of p53 in order to indirectly impact p53 function [95, 148, 193-197]. The 
role of p53 in hypoxia has been extensively studied. While there are issues with 
interpreting the data due to variations in what different groups define as hypoxia (i.e., 
0.01% O2 vs 10% O2), the consensus is that HIF1a binds to p53 in hypoxia and prevents 
the ubiquitination of p53 by Mdm2 [95, 167, 169, 198-202]. Due to the intricate web of 
feedback loops and interactions surrounding the p53/Mdm2/HIF/VHL signaling axes, it 
has been previously suggested that there is some interaction between VHL and Mdm2 
that would be important for cancer signaling [173]. 
In addition to the previously reported genes involved in cell cycle arrest and 
apoptosis, we show in a subset of patients with clear cell renal cell carcinoma that VHL is 
important for the activation of p53 for a plethora of genes involved in angiogenesis. It is 
unclear at the moment if different VHL disease types will have different levels of p53 
activation. However, the K159E VHL mutant used in our study was isolated from a 
patient with a Type 2C VHL disease mutation [126]. Importantly, Type 2C VHL disease 
does not develop kidney cancer [120]. The mutations for different VHL disease types are 
categorized based on the clinical presentation of the disease as opposed to the location of 
the mutation on the gene [118]. It will be interesting to see in the future how different 
VHL disease mutants respond to this signaling pathway. Every mutant of VHL that has 
been tested has a defect in binding to fibronectin. Neddylation of VHL is required for 
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binding to fibronectin, but VHL in complex with fibronectin is not neddylated [126]. It is 
possible that some disease causing mutations of VHL may actually protect against kidney 
cancer by changing the binding activity of the protein.  
p53 is rarely mutated in renal cell carcinoma, but many target genes of p53 are 
downregulated in these tumors [182]. For many years, there were conflicting reports on 
the effect of p53 upregulation and subsequent Mdm2 upregulation in renal cell 
carcinomas. However, a consensus has recently emerged that shows a correlation 
between p53 upregulation and disease progression [reviewed in [203]]. This correlation 
suggests that there are other pathways involved in shutting down the wild type p53 
signaling axis. VHL is a likely source of p53 dysregulation as it is highly mutated in renal 
cell carcinoma and is a known coactivator of p53 [173]. But that does not explain the 
incidence of tumors that maintain both wild type p53 and VHL. Renal cell carcinoma 
patients with high protein levels of both p53 and Mdm2 have the poorest overall survival 
[204]. This data, combined with our study, highlights the importance of Mdm2 signaling 
in renal cell carcinoma. We have presented one mechanism that Mdm2 uses to disrupt 
normal p53 signaling to promote angiogenesis and tumor progression. Additionally, 
Mdm2 is able to neddylate p53, which increases the stability of p53 but makes it inactive 
[47]. The neddylation of p53 by Mdm2 could be part of the reason why high levels of 
wild type p53 are associated with poor outcomes in ccRCC. It is likely that there are 
other mechanisms to guarantee redundancy in the function of Mdm2, and these are 
currently being explored. Our study provides the impetus for Mdm2 to be considered as a 
prognostic marker and potential therapeutic target in renal cell carcinomas.   
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5. Discussion and Future Directions 
5.1 Contributions to the field and status of research 
 The field of p53 research has been studying the interplay between different p53 
family members since the characterization of p53 as a tumor suppressor. I elaborated on 
some of these interactions in the section on p53 family members, but until recently this 
field has been hindered by a mischaracterization of p53/p73 interaction. In 1999, Di 
Como et al. published findings that suggested mutant p53 (specifically R175H and 
R248W) could bind to p73 and inhibit the tumor suppressive functions of p73 [135]. This 
research led to the widespread belief that mutations of TP53 confer a gain of function to 
the protein by functioning as an oncoprotein and inhibiting the other p53 family 
members, p63 and p73 [135, 136]. The field as a whole had accepted these findings as 
dogma, and research progressed to investigate mutant p53 gain of function mutations 
[205, 206]. However, reexamination of the original study by Di Como et al. led us to 
believe that there may be some crucial components missing.  
 The p53 protein is highly regulated at the posttranslational level and these 
modifications often dictate the function of p53 in specific contexts. Di Como et al. 
examined the p53/p73 interaction under conditions of transient transfection, but they did 
not investigate specific signaling pathways. Furthermore, the immunoprecipitations done 
in this study were performed 48 hours after transfection. The p53 apoptotic response can 
be very rapid, so it is also possible that they simply missed the window of time in which 
p53 and p73 interact. Our study of p53 family member interactions focused on specific 
signaling events that might cause wild type p53 to interact with p73. We analyzed various 
phosphorylation sites that are known to be important for apoptosis, and then examined 
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p53-p73 complex formation under cell signaling conditions when those sites would be 
phosphorylated. As expected, we identified a phosphorylation site that is important for 
p53/p73 interaction. When the kinase JNK is active, wild type p53 is phosphorylated at 
Thr81, resulting in a conformational change that is reflective of mutant p53 and is 
permissive of binding to p73. The interaction between wild type p53 and p73 results in a 
synergistic induction of apoptosis [1].  
 Our study helps to refine the dogma of p53 family member interactions. It 
provides the impetus to reexamine the implications of p53 family member interactions in 
different contexts, and corrects the long held belief in the field that wild type p53 does 
not interact with p73. The p53 pathway has been the focus of many therapeutic efforts to 
treat cancer, though this approach has seen little success to date. Our data add another 
level of information to the enigma of targeting p53, and provides a fresh take on this 
well-known pathway. In addition to the synergistic effect of wild type p53 and p73 
working together, our lab is interested in other mechanisms of p53 activation and 
regulation of p53 activation at the posttranslational level. This work led us to examine a 
somewhat unique situation that is seen clinically in clear cell renal cell carcinomas.  
In ccRCC, TP53 mutations are very rare, but p53 target genes are still 
downregulated [182].  Another common feature of ccRCC is mutation of the VHL 
protein [122]. In 2006, Roe et al. showed that VHL could bind to p53 in response to DNA 
damage, resulting in the stabilization and transactivation of p53 [173]. They did not, 
however, examine the p53/VHL pathway in hypoxia, which is a major component of the 
highly vascularized RCC tumors. We showed that in response to hypoxia, VHL binds to 
p53 and activates transcription of anti-angiogenesis p53 target genes. Additionally, the 
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p53/VHL interaction is inhibited by neddylation of VHL at K159 by Mdm2. Mdm2 
neddylates VHL in the region of the protein that is required for its binding with p53, 
effectively blocking this interaction. Clinical data from our study supports our hypothesis 
that mutations in the alpha domain of VHL, which binds directly to Mdm2, results in 
increased RNA expression of p53 target genes involved in inhibiting angiogenesis.  
Due to the unique characteristics in the p53 pathway in ccRCC, many groups have 
attempted to identify methods to use the status of p53 and/or Mdm2 as a prognostic 
marker for these patients [203, 204]. These studies offer conflicting reports on the use of 
either p53 or Mdm2 as effective indicators of disease free progression or overall survival. 
We introduce another potential method of predicting outcomes in ccRCC through the 
utilization of immunohistochemistry for activated (Ac-K382) p53 and TSP-1 protein 
levels. This staining approach could be an effective method of determining the 
angiogenic potential of a tumor. Another aspect of the p53/VHL pathway that is still 
under investigation, is the involvement of the Mdm2 family member, MdmX.  
MdmX is known to support the ubiquitin and nedd8 E3 ligase activity of Mdm2 
[48, 207-209]. In another study from our lab, I showed that phosphorylation of Mdm2 by 
Src at Y281 and Y302 results in increased binding between Mdm2 and MdmX (Figure 
35). Phosphorylation of Mdm2 at Y281 and Y302 by Src converts Mdm2 to a 
neddylating E3 ligase and MdmX is able to increase the efficiency of Mdm2-mediated 
neddylation of p53 [47, 48]. Following this logic, we presumed that MdmX may also 
increase the nedd8 E3 ligase activity of Mdm2 in order to neddylate VHL. Indeed, in a 
cell free assay using recombinant proteins, there was a marked increase in the neddylated 
form of VHL when MdmX was included in the reaction (Figure 36). These findings 
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support a potentially important function of Mdm2 and MdmX in the progression of 
ccRCC by inhibiting the VHL-p53 pathway.   
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Figure 35. Phosphorylation of Mdm2 by Src increases binding to MdmX. GST-pulldown for MdmX using 
Src, GST, GST-MdmX, and His-Mdm2 and Western blotted for Mdm2, MdmX, and Src. Data published in 
[48] 
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Figure 36. MdmX increases the Mdm2-mediated neddylation of VHL. Cell free neddylation assay using 
recombinant proteins. Reactions were separated by SDS-PAGE and analyzed by Western blot.  
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5.2 Evidence for an Mdm2-VHL feedback loop 
 
 While researching the effect of VHL mutations on various p53 pathway target 
genes, I noticed that mRNA for MDM2 was increased in the alpha mutation group 
(Figure 37). Since p53 can activate transcription of MDM2, this is not entirely surprising. 
However, MDM2 mRNA is ordinarily not altered significantly in tumors, even if there is 
a large change in corresponding protein abundance [39]. We decided to investigate the 
change in MDM2 mRNA to determine if VHL was somehow altering the transcription of 
MDM2. To this end, we utilized a reporter gene for the P2 promoter of MDM2, which is 
the promoter responsible for transcription above basal levels. The luciferase activity of 
786-O cells with or without VHL under normoxia and hypoxia was tested. MDM2 is 
known to undergo a transient increase in transcription in response to hypoxia, and we saw 
this increase in our own data (Figure 38). We also saw that cells with VHL had a marked 
decrease in MDM2 P2 promoter activity compared to the control. The impact of VHL on 
MDM2 P2 promoter activity was somewhat surprising to us as other groups have 
postulated the existence of a VHL-Mdm2 feedback loop, but no data has been published 
on an Mdm2/VHL pathway. 
To determine if steady state RNA levels were affected by VHL, RNA was 
harvested from 786-O cells with or without VHL subjected to normoxia or hypoxia and 
performed PCR following reverse transcription. We first used primers for the start site of 
MDM2 and a site 639 bases downstream to amplify the gene. While the overall level of 
RNA was no different between all conditions tested, we did notice the appearance of a 
lower migrating band of MDM2 RNA (Figure 39A).    
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Figure 37. MDM2 mRNA levels are affected by the mutation status of VHL. Log counts per million for 
MDM2. Only samples with wild-type p53 were included in the analysis. Error bars represent SEM. P values 
were calculated using an unpaired t test. 
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Figure 38. VHL inhibits the P2 promoter of Mdm2 in normoxia and hypoxia. Luciferase assay for the P2 
promoter of Mdm2 in 786-O cells treated subjected to hypoxia. Means are plotted as relative luciferase 
units and calculated from three biological replicates. Error bars represent the standard deviation.  
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 There are many alternatively spliced isoforms of MDM2, and these isoforms are 
especially active in cancer or in conditions of stress, such as hypoxia [210-212]. From the 
difference in size of the RNA bands combined with available information on different 
splice forms of MDM2, we were able to form a hypothesis as to which, if any, splice form 
this band corresponded to. We hypothesized that the lower migrating band represented 
isoform F of MDM2 (Figure 39B and 39C). Of note, isoform F is almost identical to the 
full length version except for its loss of the p53 binding domain. To test our hypothesis, 
the same sample was amplified with primers directed at 174 bases downstream of the 
start site and 639 bases downstream of the start site. The primer directed at 174 bases 
downstream of the start site would not be able to bind to the lower band of MDM2 if it 
corresponded to isoform F. Amplification with this primer set resulted in the loss of the 
lower band of MDM2, supporting our hypothesis for the induction of isoform F (Figure 
39A and 39C). Since it is lacking most of the p53 binding domain, we believe that 
isoform F of Mdm2 will have a much different function than full length Mdm2. It is 
possible that isoform F functions primarily to regulate VHL, creating a feedback loop 
within this already complex system. While the region of Mdm2 that binds to VHL is 
currently unknown, the acidic domain of Mdm2 is a likely candidate. The three lysine 
residues within the a domain of VHL, which is the region of VHL that binds to Mdm2, 
would create a positive charge on the protein in that region. This positive charge may be 
sufficient to attract the negatively charged acidic domain of Mdm2. If this is indeed the 
case, then the isoform F of Mdm2 should maintain its full binding capacity for VHL.   
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Figure 39. VHL and hypoxia cause the expression of an alternatively spliced isoform of MDM2. (A) RNA 
was harvested from 786-O cells with or without VHL in normoxia or hypoxia and PCR for Mdm2 was 
performed following reverse transcription. START à213 corresponds to a primer pair directed to the start 
site of MDM2 and another site 639 bases downstream. 58 à represents a primer pair directed to sites 174 
and 639 base pairs downstream of the start site. (B) Map of the full length Mdm2 protein. (C) Map of the 
alternatively spliced isoform F Mdm2 protein. 
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 In order to test if these changes at the RNA level corresponded to a change at the 
protein level, 786-O cells with or without VHL were subjected to a time course of 
normoxia or hypoxia and analyzed Mdm2 protein by Western blot. Mdm2 protein was 
less abundant with VHL present, and that a lower migrating band of Mdm2 protein began 
to appear as hypoxia progressed (Figure 40). The size of the lower migrating band 
corresponds to the previously determined apparent size of isoform F [210]. To determine 
if the pathway leading to the potential isoform F was indeed some sort of feedback loop, 
we examined the ability of Mdm2 to ubiquitinate VHL, as is the case with the 
autoregulatory feedback loop between Mdm2 and p53. H1299 cells were transiently 
transfected with Mdm2, VHL, Abl, and His-ubiquitin, followed by an Ni-NTA pulldown 
under denaturing conditions. Mdm2 is able to ubiquitinate VHL, and this ubiquitination 
increases with Abl transfection (Figure 41). Abl phosphorylates Mdm2 and activates its 
ubiquitin E3 ligase function.   
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Figure 40. VHL and hypoxia cause the expression of an alternatively spliced isoform of Mdm2 protein. 
786-O cells were subjected to a time course of normoxia or hypoxia and harvested at the indicated times. 
Lysates were separated with SDS-PAGE and Western blotted for Mdm2 and actin. 
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Figure 41. Mdm2 ubiquitinates VHL. Ni-NTA pulldown for His-nedd8 in H1299 cells in a transient 
transfection. Samples were separated with SDS-PAGE and analyzed by Western blot for VHL. 
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 These data support an alternative feedback loop for Mdm2 and VHL. VHL both 
inhibits transcription of MDM2 and increases the abundance of an alternative isoform of 
Mdm2 that is unable to bind to p53. Conversely, Mdm2 ubiquitinates and destabilizes 
VHL. The mechanisms governing the Mdm2-VHL feedback loop are still being 
investigated, as is the function of the Mdm2 isoform F. It is possible that isoform F of 
Mdm2 is responsible for regulation of VHL, as it has lost its ability to bind to p53. The 
inhibition of transcription from the P2 promoter of MDM2 could be happening through 
the transcription factor Sp1. VHL has been shown to bind to Sp1, resulting in inhibition 
of the transcription of VEGF [213, 214]. The P2 promoter of MDM2 contains a binding 
site for Sp1 [215], so it is possible that VHL is reducing the transcription of both MDM2 
and VEGF by binding Sp1 and sequestering it away from the promoters of these genes. A 
naturally occurring single nucleotide polymorphism (SNP) of the MDM2 promoter 
(SNP309) has been shown to increase its affinity for Sp1, resulting in increased risk for 
cancer [215]. Interestingly, a second SNP at 285 of the MDM2 promoter has been shown 
to reduce the risk of breast, ovarian, and endometrial cancer. SNP285 occurs in a region 
where an estrogen response element overlaps with the Sp1 binding site, suggesting that 
the Mdm2 pathway may have large implications in gender-specific tumor formation 
[216]. In addition to the inhibition of the P2 promoter of MDM2 by VHL, we also believe 
that the P1 promoter is becoming active under hypoxia due to the fact that the lower 
migrating band of Mdm2 mRNA and protein was also seen in the vector control cells. 
PTEN has previously been shown to inhibit the P1 promoter of MDM2 independently of 
p53 [217]. Recent data suggests that hypoxia is able to modulate the activity of PTEN, 
resulting in an increase in EMT [218, 219]. These data support our model where VHL 
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inhibits the P2 promoter of MDM2, and hypoxia activates the P1 promoter by alleviating 
the PTEN inhibition. Other groups have shown that elevated MDM2 from the P1 
promoter is correlated with poor prognosis in glioblastomas and pancreatic ductal 
adenocarcinomas [220, 221]. Our lab recently published that Mdm2 is able to promote 
EMT independently of p53, and it is possible that this function is due in part to elevated 
P1 transcription of MDM2 [101]. As previously mentioned, the isoform of Mdm2 that we 
believe is being produced under hypoxia has lost the p53 binding domain, but maintains 
the region of binding to VHL and would also maintain the EMT promoting functions. 
The Mdm2-VHL alternative feedback loop is an ongoing project in the lab, but the 
current findings and hypothesis are presented in (Figure 42).  
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Figure 42.   Schematic of the VHL-Mdm2 alternative feedback loop. 
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5.3 Conclusions and summary of findings 
 These data contribute new information on the activation of the tumor suppressor 
protein p53. Different signaling pathways and cell stresses have been examined for the 
role they play in activating downstream, p53-dependent responses. The work herein has 
provided an explanation for the inhibition of p53 pathway targets in tumors that have 
wild type p53, such as ccRCC. The p53-VHL pathway could also be active in tumors that 
maintain wild type p53, wild type VHL, and normal protein levels of Mdm2. My research 
highlights the importance of cell signaling conditions in tumors as opposed to the 
mutation status alone. The pathways presented in this dissertation can both suppress and 
promote tumor progression regardless of the mutation status of the tumor. Additionally, 
there are many intricate and overlapping methods of activating these pathways. For 
instance, while Mdm2 can neddylate VHL directly to inhibit its interaction with p53, 
Mdm2 is also able to neddylate p53 directly. Whether through neddylation of VHL or 
neddylation of p53, Mdm2 is able to block transcriptional activity of p53 through its 
neddylating function. Mdm2 is also able to ubiquitinate both p53 and p73, resulting in 
degradation of both. If p53 is protected from Mdm2-mediated ubiquitination by VHL or 
ATM, then Mdm2 is still able to inhibit the p53-p73 pathway by ubiquitinating p73. 
These redundant mechanisms are abundant in cell signaling. 
Another overlapping mechanism of angiogenesis suppression occurs between 
VHL and p73. In normoxia, VHL destabilizes HIF1a via ubiquitination which blocks its 
proangiogenic functions. In hypoxic conditions HIF1a is relieved of VHL-mediated 
degradation and is free to activate transcription of proangiogenic target genes such as 
VEGF.  However, under hypoxia p73 is able to bind to Mdm2 and recruit it to HIF1a in 
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order to promote ubiquitination of HIF1a [174]. The regulation of Mdm2 by p73 is in 
part due to the regulation of SIAH1, an E3 ubiquitin ligase for p73. In normoxia, SIAH1 
ubiquitinates p73 and promotes its degradation. But in hypoxia, stabilized HIF1a can 
bind to SIAH1 and inhibit its suppression of p73, which in turn allows p73 to promote 
ubiquitination of HIF1a through Mdm2 [174, 222, 223]. The ubiquitination of HIF1a via 
p73 stabilization is independent of VHL [222], highlighting the fact that there are 
multiple tumor suppressors tasked with overlapping, but independent, functions to keep 
tumors from growing. Of note, the experiment showing that p73 stabilization under 
hypoxia is independent of VHL was done transiently in H1299 cells with siRNA against 
VHL. Since transient transfection can also cause a DNA damage response, it is possible 
that VHL would be important for p73 stabilization in different signaling conditions or 
that stabilization of p73 by VHL would become more evident with a better knockdown of 
VHL. 
 In summary, I have shown new mechanisms of p53 activation by the tumor 
suppressor proteins p73 and VHL. In response to cell stress that activates the kinase JNK, 
p53 and p73 form a complex that has synergistic activity in promoting apoptosis. JNK is 
responsive to a wide variety of cell stress including growth factors, DNA damage, and 
oxidative stress caused by hypoxia. I have shown another mechanism of p53 activation in 
response to hypoxia that involves the tumor suppressor protein VHL. VHL binds to p53 
and activates transcription of a variety of anti-angiogenic targets of p53 in order to 
suppress blood vessel formation and tumor growth. The VHL-p53 pathway has also been 
shown to be active in response to DNA damage [173]. Combined, our data show two 
unique and potentially overlapping mechanisms of p53 activation which can both be 
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potentially disrupted by the oncoprotein Mdm2 through ubiquitination or neddylation of 
p73 and VHL. Our work provides a fresh take on the oncogenic functions of Mdm2 and 
gives rationale for considering new approaches in targeting Mdm2 therapeutically. 
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